

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019368318 B2**

(54) Title
Methods, devices, and systems for physiological parameter analysis

(51) International Patent Classification(s)
A61B 5/145 (2006.01) **A61M 5/172** (2006.01)
A61B 5/00 (2006.01) **G01N 33/72** (2006.01)

(21) Application No: **2019368318** (22) Date of Filing: **2019.10.25**

(87) WIPO No: **WO20/086934**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/750,957	2018.10.26	US

(43) Publication Date: **2020.04.30**

(44) Accepted Journal Date: **2023.02.16**

(71) Applicant(s)
Abbott Diabetes Care Inc.

(72) Inventor(s)
XU, Yongjin

(74) Agent / Attorney
FPA Patent Attorneys Pty Ltd, Level 19, South Tower 80 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
WO 2018/156584 A1



(51) International Patent Classification:

A61B 5/145 (2006.01) A61M 5/172 (2006.01)
A61B 5/00 (2006.01) G01N 33/72 (2006.01)

(72) Inventor: XU, Yongjin; 5480 Sherwood Way, San Ramon, California 94582 (US).

(21) International Application Number:

PCT/US2019/058014

(74) Agent: KAISER, Iona et al.; 909 Fannin St., Suite 2700, Houston, Texas 77010 (US).

(22) International Filing Date:

25 October 2019 (25.10.2019)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/750,957 26 October 2018 (26.10.2018) US

(71) Applicant: ABBOTT DIABETES CARE INC. [US/US];
1360 South Loop Rd., Alameda, California 94502 (US).

(54) Title: METHODS, DEVICES, AND SYSTEMS FOR PHYSIOLOGICAL PARAMETER ANALYSIS




FIG. 1

(57) Abstract: A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value including: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (k_{age}) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the k_{age} . Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

06 August 2020 (06.08.2020)

METHODS, DEVICES, AND SYSTEMS FOR PHYSIOLOGICAL PARAMETER ANALYSIS

BACKGROUND

[0001] The measurement of various analytes within an individual can sometimes be vital for monitoring the condition of their health. During normal circulation of red blood cells in a mammal such as a human, glucose molecules attach to hemoglobin, which is referred to as glycosylated hemoglobin (also referred to as glycated hemoglobin). The higher the amount of glucose in the blood, the higher the percentage of circulating hemoglobin molecules with glucose molecules attached. The level of glycosylated hemoglobin is increased in the red blood cells of subjects with poorly controlled diabetes mellitus. Since glucose molecules stay attached to hemoglobin for the life of the red blood cells (normally no more than about 120 days), the level of glycosylated hemoglobin reflects an average blood glucose level over that period.

[0002] Most of hemoglobin is a type called HbA. When glucose molecules attach to HbA molecules, glycosylated HbA is formed, which is referred to as HbA1. HbA1 has three components: HbA1a, HbA1b, and HbA1c. Because a glucose binds more strongly and to a higher degree to HbA1c than HbA1a and HbA1b, a measure of HbA1c in blood (HbA1c test) is often used as an indication of a subject's average blood glucose level over a 120 day period (the average lifetime of a red blood cell). The HbA1c test is performed by drawing a blood sample from a subject at a medical professional's office, which is then analyzed in a laboratory. The HbA1c test may be used as a screening and diagnostic test for pre-diabetes and diabetes. The HbA1c test may be conducted multiple times over a time period to monitor the health of a subject for diagnosis and/or therapy decisions.

[0003] Commercially available in vitro blood glucose test strips and in vivo sensors (and their related devices and systems) provide glucose level measurements with varying degrees of measurement frequency. These devices can also provide an estimated HbA1c ("eHbA1c") value. While both in vitro and in vivo sensors (and their related devices and systems) are known to be reliable and accurate, when comparisons have been made between HbA1c values and eHbA1c values, a notable discrepancy between the two measurements has been observed. Existing eHbA1c

methods and devices, with their reliance on static models, and/or broad assumptions and/or less robust data, are generally considered to be less reliable than HbA1c test results. However, HbA1c determination is inconvenient and uncomfortable for subjects, who must periodically have blood drawn for HbA1c tests and then wait for the results. Additionally, subjects and healthcare providers would benefit from a more accurate eHbA1c that would allow both subjects and their health care providers to monitor and respond to any changes in eHbA1c. Thus, a need exists for improved eHbA1c methods and devices.

[0003a] Reference to any prior art in the specification is not an acknowledgement or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be combined with any other piece of prior art by a skilled person in the art.

[0003b] By way of clarification and for avoidance of doubt, as used herein and except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude further additions, components, integers or steps.

SUMMARY

[0003c] According to a first aspect of the invention, there is provided a method comprising: measuring a plurality of first glucose levels in a bodily fluid over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring a reticulocyte production index (RPI) value; calculating a red blood cell elimination constant (k_{age}) based on the RPI value, wherein $k_{age} = RPI * (3.47 \text{ day}^{-1}) * (1 - \ln 2)$; calculating, using (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the k_{age} , at least one first physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K); and adjusting a glucose level target based on the at least one first physiological parameter.

[0003d] According to a second aspect of the invention, there is provided a system comprising: an analyte sensor configured to measure a glucose level in a bodily fluid; and a monitoring device comprising: one or more processors; and a

memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: receive a plurality of first glucose levels in the bodily fluid over a first time period from the analyte sensor; receive a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; receive a reticulocyte production index (RPI) value; determine a red blood cell elimination constant (k_{age}) based on the RPI value, wherein $k_{age} = RPI * (3.47 \text{ day}^{-1}) * (1 - \ln 2)$; determine, based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) k_{age} at least one first physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K); and adjust a glucose level target based on the at least one first physiological parameter.

BRIEF DESCRIPTION OF THE DRAWINGS

[0004] The following figures are included to illustrate certain aspects of the present disclosure, and should not be viewed as exclusive embodiments. The subject matter disclosed is capable of considerable modifications, alterations, combinations, and equivalents in form and function, without departing from the scope of this disclosure.

[0005] FIG. 1 illustrates an example time line 100 illustrating collection of at least one HbA1c value and a plurality of glucose levels for a time period.

[0006] FIG. 2 illustrates an example of a physiological parameter analysis system for providing physiological parameter analysis in accordance with some of the embodiments of the present disclosure.

[0007] FIG. 3 illustrates an example of a physiological parameter analysis system for providing physiological parameter analysis in accordance with some of the embodiments of the present disclosure.

[0008] FIG. 4 illustrates an example of a calculated HbA1c (cHbA1c) report that may be generated as an output by a physiological parameter analysis system in accordance with some of the embodiments of the present disclosure.

[0009] FIG. 5A illustrates an example of a method of determining a personalized-target glucose range in accordance with some of the embodiments of the present disclosure.

[0010] FIG. 5B illustrates an example of a personalized-target glucose range report that may be generated as an output by a physiological parameter analysis system in accordance with some of the embodiments of the present disclosure.

[0011] FIG. 6 illustrates an example of a personalized-target average glucose report that may be generated as an output by a physiological parameter analysis system in accordance with some of the embodiments of the present disclosure.

[0012] FIG. 7 illustrates an example of a glucose pattern insight report that may be generated as an output by a physiological parameter analysis system in accordance with some of the embodiments of the present disclosure.

[0013] FIG. 8 illustrates an example of an in vivo analyte monitoring system in accordance with some of the embodiments of the present disclosure.

[0014] FIGS. 9A-C illustrate a comparison between the laboratory HbA1c levels at day 200 (± 5 days) relative to the estimated HbA1c (eHbA1c) values for two different models (9A and 9B) and calculated HbA1c (cHbA1c) values for the kinetic model of the present disclosure (9C).

[0015] FIG. 10 illustrates an example study subject's data with the measured glucose levels (solid line), laboratory HbA1c readings (open circles), cHbA1c model values (long dashed line), and 14-day eHbA1c model values (dotted line).

[0016] FIG. 11 illustrates the relationship between steady glucose and equilibrium HbA1c (1) as determined using the standard conversion of HbA1c to estimated average glucose (dashed line with error bars) and (2) as measured for the 90 participants (solid lines).

[0017] FIG. 12 illustrates the relationship between K (dL/mg) and mean glucose level target (mg/dl) for varying HbA1c target values using the kinetic model of the present disclosure.


DETAILED DESCRIPTION

[0018] The present disclosure generally describes methods, devices, and systems for determining physiological parameters related to the kinetics of red blood cell glycation, elimination, and generation and reticulocyte maturation within the

body of a subject. Such physiological parameters can be used, for example, to calculate a more reliable calculated HbA1c and/or a personalized target glucose range, among other things.

Kinetic Model

[0019] Formula 1 illustrates the kinetics of red blood cell glycation, elimination, and generation, where "G" is free glucose, "R" is a non-glycated red blood cell, and "GR" is a glycated red blood cell. The rate at which glycated red blood cells (GR) are formed is referred to herein as a red blood cell glycation rate constant (k_{gly} typically having units of $dL \cdot mg^{-1} \cdot day^{-1}$).



Formula 1

[0020] Over time, red blood cells including the glycated red blood cells are continuously eliminated from a subject's circulatory system and new red blood cells are generated, typically at a rate of approximately 2 million cells per second. The rates associated with elimination and generation are referred to herein as a red blood cell elimination constant (k_{age} typically having units of day^{-1}) and a red blood cell generation rate constant (k_{gen} typically having units of M^2/day), respectively. Since the amount of red blood cells in the body is maintained at a stable level most of time, the ratio of k_{age} and k_{gen} should be an individual constant that is the square of red blood cell concentration.

[0021] As described previously, HbA1c is a commonly used analyte indicative of the fraction of the glycated hemoglobin found in red blood cells. Therefore, a kinetic model can be used, for example, to derive a calculated HbA1c based on at least the glucose levels measured for a subject. However, the kinetic

model can also be applied to HbA1. For simplicity, HbA1c is uniformly used herein, but HbA1 could be substituted except in instances where specific HbA1c values are used (e.g., see Equations 15 and 16). In such instances, specific HbA1 values could be used to derive similar equations.

[0022] Typically, when kinetically modeling physiological processes, assumptions are made to focus on the factors that affect the physiological process the most and simplify some of the math.

[0023] The present disclosure uses only the following set of assumptions to kinetically model the physiological process illustrated in Formula 1. First, glucose concentration is high enough not to be affected by the red blood cell glycation reaction. Second, there is an absence of abnormal red blood cells that would affect HbA1c measurement, so the hematocrit is constant for the period of interest. This assumption was made to exclude extreme conditions or life events that are not normally present and may adversely affect the accuracy of the model. Third, the glycation process has first order dependencies on both red blood cell and glucose concentrations. Fourth, newly-generated red blood cells have a negligible amount of glycated hemoglobin, based on previous reports that reticulocyte HbA1c is very low and almost undetectable. Fifth, red blood cell production inversely correlates with total cellular concentration, whereas elimination is a first order process.

[0024] With the five assumptions described above for this kinetic model, the rate of change in glycated and non-glycated red blood cells can be modeled by differential Equations 1 and 2.

$$d[GR]/dt = k_{gly}[G][R] - k_{age}[GR] \quad \text{Equation 1}$$

$$(d[R])/dt = k_{gen}/C - k_{age}[R] - k_{gly}[G][R] \quad \text{Equation 2}$$

C is the whole population of red blood cells, where $C = [R] + [GR]$ (Equation 2a). C typically has units of M (mol/L), [R] and [GR] typically have units of M, and [G] typically has units of mg/dL.

[0025] Assuming a steady state, where the glucose level is constant and the glycated and non-glycated red blood cell concentrations remain stable ($d[GR]/dt =$

($d[R])/dt = 0$), the following two equations can be derived. Equation 3 defines the apparent glycation constant K (typically with units of dL/mg) as the ratio of k_{gly} and k_{age} , whereas Equation 4 establishes the dependency between red blood cell generation and elimination rates.

$$K = k_{gly}/k_{age} = [GR]/[G][R] \quad \text{Equation 3}$$

$$k_{gen}/k_{age} = C^2 \quad \text{Equation 4}$$

[0026] For simplicity, k_{age} is used hereafter to describe the methods, devices, and systems of the present disclosure. Unless otherwise specified, k_{gen} can be substituted for k_{age} . To substitute k_{gen} for k_{age} , Equation 4 would be rearranged to $k_{gen} = k_{age} * C^2$.

[0027] HbA1c is the fraction of glycated hemoglobin as shown in Equation 5.

$$HbA1c = [GR]/C = (C - [R])/C \quad \text{Equation 5}$$

[0028] In a hypothetical state when a person infinitely holds the same glucose level, HbA1c in Equation 5 can be defined as "equilibrium HbA1c" (EA) (typically reported as a % (e.g., 6.5%) but used in decimal form (e.g., 0.065) in the calculations). For a given glucose level, EA (Equation 6) can be derived from Equations 2a, 3, and 5.

$$EA = (k_{gly}[G])/(k_{age} + k_{gly}[G]) = [G]/(K^{-1} + [G]) \quad \text{Equation 6}$$

[0029] EA is an estimate of HbA1c based on a constant glucose concentration $[G]$ for a long period. This relationship effectively approximates the average glucose and HbA1c for an individual having a stable day-to-day glucose profile. EA depends on K , the value of which is characteristic to each subject. Equation 6 indicates that the steady glucose is not linearly correlated with EA. Steady glucose

and EA may be approximated with a linear function within a specific range of glucose level, but not across the full typical clinical range of HbA1c. Furthermore, in real life with continuous fluctuations of glucose levels, there is no reliable linear relationship between laboratory HbA1c and average glucose for an individual.

[0030] Others have concluded this also and produced kinetic models to correlate a measured HbA1c value to average glucose levels. For example, The American Diabetes Association has an online calculator for converting HbA1c values to estimated average glucose levels. However, this model is based on an assumption that k_{age} and k_{gly} do not substantially vary between subjects, which is illustrated to be false in Example 1 below. Therefore, the model currently adopted by the American Diabetes Association considers k_{age} and k_{gly} as constants and not variable by subject.

[0031] A more recent model by Higgins et al. (Sci. Transl. Med. 8, 359ra130, 2016) has been developed that removed the assumption that red blood cell life is constant. However, the more recent model still assumes that k_{gly} does not substantially vary between subjects.

[0032] In contrast, both k_{age} and k_{gly} are variables for the kinetic models described herein. Further, a subject's k_{gly} is used in some embodiments to derive personalized parameters relating to the subject's diabetic condition and treatment (e.g., a medication dosage, a supplement dosage, an exercise plan, a diet/meal plan, and the like).

[0033] Continuing with the kinetic model of the present disclosure, the HbA1c value ($HbA1c_t$) at the end of a time period t (Equation 7) can be derived from Equation 1, given a starting HbA1c ($HbA1c_0$) and assuming a constant glucose level $[G]$ during the time period.

$$HbA1c_t = EA + (HbA1c_0 - EA) * e^{-(k_{gly}[G] + k_{age})t} \quad \text{Equation 7}$$

[0034] To accommodate changing glucose levels over time, each individual's glucose history is approximated as a series of time intervals t_i with corresponding average glucose levels $[G_i]$. Applying Equation 7 recursively, $HbA1c_z$ at the end of time interval t_z can be expressed by Equation 8 for numerical calculations.

$$HbA1c_z = EA_z(1 - D_z) + \sum_{i=1}^{z-1} [EA_i(1 - D_i) \prod_{j=i+1}^z D_j] + HbA1c_0 \prod_{j=1}^z D_j \quad \text{Equation 8}$$

where the decay term $D_i = e^{-(k_{gly}[G_i] + k_{age})t_i}$ (Equation 8a).

[0035] When solving for k_{age} and k_{gly} using Equations 6, 7, or 8, k_{age} and k_{gly} may be bounded to reasonable physiological limits, by way of nonlimiting example, of $5.0 \times 10^{-6} \text{ dL} \cdot \text{mg}^{-1} \cdot \text{day}^{-1} < k_{gly} < 8.0 \times 10^{-6} \text{ dL} \cdot \text{mg}^{-1} \cdot \text{day}^{-1}$ and $0.006 \text{ day}^{-1} < k_{age} < 0.024 \text{ day}^{-1}$. Additionally or alternatively, an empirical approach using the Broyden-Fletcher-Goldfarb-Shanno algorithm can be used with estimated initial values for k_{gly} and k_{age} (e.g., $k_{gly} = 4.4 \times 10^{-6} \text{ dL} \cdot \text{mg}^{-1} \cdot \text{day}^{-1}$ and $k_{age} = 0.0092 \text{ day}^{-1}$). The more glucose level data points and measured HbA1c data points, the more accurate the physiological parameters described herein are.

[0036] The value for time interval t_i can be selected (e.g., by a user or developer, or by software instructions being executed on one or more processors) based on a number of factors that can vary between embodiments and, as such, the value of time interval t_i may vary. One such factor is the duration of time from one glucose data value (e.g., a measured glucose level at a discrete time, a value representative of glucose level for a particular time period across multiple discrete times, or otherwise) to another within the individual's glucose history. That duration of time between glucose data values can be referred to as time interval t_g . Time interval t_g can vary across the individual's glucose history such that a single glucose history can have a number of different values for time interval t_g . Numerous example embodiments leading to different values of time interval t_g are described herein. In some embodiments of glucose monitoring systems, glucose data points are determined after a fixed time interval t_g (e.g., every minute, every ten minutes, every fifteen minutes, etc.) and the resulting glucose history is a series of glucose data points with each point representing the glucose at the expiration of or across the fixed time interval t_g (e.g., a series of glucose data points at one minute intervals, etc.).

[0037] In other embodiments, glucose data points are taken or determined at multiple different fixed time intervals t_g . For example, in some flash analyte monitoring systems (described in further detail herein), a user may request glucose data from a device (e.g., a sensor control device) that stores glucose data within a recent time period (e.g., the most recent fifteen minutes, the most recent hour, etc.) at a first relatively shorter time interval t_g (e.g., every minute, every two minutes), and all other data (in some cases up to a maximum of eight hours, twelve hours, twenty-four hours, etc.) outside of that recent time period is stored at a second relatively longer time interval t_g (e.g., every ten minutes, every fifteen minutes, every twenty minutes, etc.). The data stored at the second, relatively longer time interval can be determined from data originally taken at the relatively shorter time interval t_g (e.g., an average, median, or other algorithmically determined value). In such an example the resulting glucose history is dependent on how often a user requests glucose data, and can be a combination of some glucose data points at the first time interval t_g and others at the second time interval t_g . Of course, more complex variations are also possible with, for example, three or more time intervals t_g . In some embodiments, glucose data collected with ad hoc adjunctive measurements (e.g., a finger stick and test strip) can also be present, which can result in even more variations of time interval t_g .

[0038] An example analysis performed on glucose histories for a sample of subjects (approximately 400) where glucose data points were generally present at time intervals t_g of one to fifteen minutes, indicated that a value for time interval t_i within the range of three hours (or about three hours) to twenty four hours (or about twenty four hours) could be selected without significant loss of accuracy. Generally, shorter time intervals t_i resulted in higher accuracy than longer ones, and time interval t_i values closer to three hours were the most accurate. Time interval t_i values less than three hours may begin to exhibit loss of accuracy due to numerical rounding errors. These rounding errors can be reduced by using longer digit strings at the expense of processing load and computing time. It should be noted that other values of time interval t_i outside of the range of 3 to 24 hours may be suitable depending on the desired accuracy levels and other factors, such as the average time interval t_g between glucose data points.

[0039] Another factor in selection of time interval t_i is the existence of gaps, or missing data, in the individual's glucose history, where the gaps are longer or significantly longer than the longest time interval t_g . The existence of one or more such gaps can potentially lead to results bias. These gaps can result, for example, from the inability to collect glucose data across a certain time period (e.g., the user was not wearing a sensor, the user forgot to scan the sensor for data, a fault occurred, etc.). The presence of gaps and their duration should be considered in selecting time interval t_i . Generally, the number and duration of gaps should be minimized (or eliminated) where possible. But since gaps of this type are often difficult to eliminate, to the extent such gaps exist, in many embodiments the selection of time interval t_i should be at least twice the duration of the largest (maximum) gap between glucose data points. For example, if time interval t_i is selected to be 3 hours, then the maximum gap should be no longer than 90 minutes, if time interval t_i is selected to be 24 hours, then the largest gap should be no longer than 12 hours, and so forth.

[0040] The value $HbA1c_z$ is the estimated HbA1c of the present kinetic model, which is referred to herein as $cHbA1c$ (calculated HbA1c) to distinguish from other $eHbA1c$ described herein.

[0041] As described previously and illustrated in Equation 8, EA_i and D_i are both affected by glucose level $[G_i]$, k_{gly} , and k_{age} . In addition, D_i depends on the length of the time interval t_i . Equation 8 is the recursive form of Equation 7. Equations 7 and 8 describe the relationship among HbA1c, glucose level, and individual red blood cell kinetic constants k_{gly} and k_{age} .

[0042] k_{age} can be directly measured through expensive and laborious methods. Herein, the kinetic model is extended to incorporate reticulocyte maturation as a method for estimating k_{age} .

[0043] Reticulocytes are immature red blood cells and typically account for about 1% of the total red blood cells. The rate at which reticulocytes mature into mature red blood cells is k_{mat} (typically having units of day^{-1}). The maturation half-life for a normal reticulocyte is about 4.8 hours, which provides for Equation 9.

$$k_{mat} = \ln 2 / (4.8 \text{ hours}) = 3.47 \text{ day}^{-1} \quad \text{Equation 9}$$

[0044] The kinetic model makes two assumptions: (1) all red blood cells are reticulocytes at time 0 and (2) reticulocytes are not eliminated (that is, reticulocytes mature to mature red blood cells and do not die). The probability density of reticulocyte age (p_{RET}) can be represented by Equation 10.

$$p_{RET}(\tau) = (k_{age}/(1 - \ln 2)) * e^{-k_{mat} * \tau} \quad \text{Equation 10}$$

where τ is the cell age.

[0045] A reticulocyte production index (RPI), also known as a corrected reticulocyte count (CRC), is the percentage of total red blood cells that are reticulocytes. Therefore, RPI is the integral of p_{RET} over cell age as shown in Equation 11, where RPI is the decimal form of the reported RPI (e.g., RPI reported at 2% is 0.02 in Equation 11).

$$RPI = \int_0^{\infty} p_{RET}(\tau) d\tau = k_{age}/(k_{mat} * (1 - \ln 2)) \quad \text{Equation 11}$$

[0046] Assuming the typical k_{mat} is 3.47 day^{-1} , k_{age} can be estimated from a measured RPI. RPI can be determined by normal methods. For example, RPI can be determined by measuring a hematocrit percentage (HM_m), measuring a percentage of reticulocytes (RP) in an RNA dyed blood smear, determining a maturation correction (MC) from the measured hematocrit percentage, and calculating the RPI based on Equation 12, where RP and HM_m is used as the percentage values not the decimal form (i.e., RP reported at 3% is 3 in the equation not 0.03).

$$RPI = (RP * HM_m / HM_n) / MC \quad \text{Equation 12}$$

where HM_n is the normal hematocrit value (typically 45).

[0047] Unless otherwise specified, the typical units described are associated with their respective values. One skilled in the art would recognize other units and the proper conversions. For example, [G] is typically measured in mg/dL but could be converted to M using the molar mass of glucose. If [G] is used in M or any other

variable is used with different units, the equations herein should be adjusted to account for differences in units.

Calculating Physiological Parameters from the Kinetic Model

[0048] Embodiments of the present disclosure provide kinetic modeling of red blood cell glycation, elimination, and generation and reticulocyte maturation within the body of a subject.

[0049] The physiological parameter k_{age} can be estimated from one or more RPI measurements. While k_{age} can be estimated using Equation 11 above from a single RPI measurement, two or more RPI measurements may increase the accuracy of the RPI value. Further, RPI can change over time, in response to treatment, and in response to the improvement or worsening of a disease state. Therefore, while RPI can be measured in any desired intervals of time (e.g., weekly to annually), preferably RPI is measured once every three to six months.

[0050] Once k_{age} is calculated, the physiological parameters k_{gly} and/or K can be estimated from the equations described herein given at least one measured HbA1c value (also referred to as HbA1c level measurement) and a plurality of glucose levels (also referred to as glucose level measurements) over a time period immediately before the HbA1c measurement.

[0051] FIG. 1 illustrates an example time line 100 illustrating a collection of at least one measured HbA1c value 102a, 102b, 102c, a plurality of glucose levels 104a and 104b, and at least one measured RPI value 110a, 110b, 110c over time periods 106 and 108.

[0052] The number of measured HbA1c values 102a, 102b, 102c needed to calculate k_{gly} and/or K depends on the frequency and duration of the plurality of glucose levels. The number of measured RPI values 110a, 110b, 110c needed to calculate k_{age} depends on the stability of individual k_{mat} and its deviation to typical k_{mat} (3.47 day^{-1}). Preferably RPI is measured once every three to six months but can be measured monthly or weekly, if needed.

[0053] In a first embodiment, one measured RPI value 110b can be used to calculate k_{age} , and one measured HbA1c 102b can be used along with the calculated k_{age} and a plurality of glucose measurements over time period 106 to calculate k_{gly}

and/or K. Such embodiments are applicable to subjects with steady daily glucose measurements for a long time period 106 (e.g., over about 200 days). K may be calculated at time point 101 with Equation 6 by replacing EA with the measured HbA1c value 102b and [G] with daily average glucose over time period 106. k_{gly} may then be calculated from Equation 3. Therefore, in this embodiment, an initial HbA1c level measurement 102a is not necessarily required.

[0054] Because a first HbA1c value is not measured, the time interval 106 of initial glucose level measurements with frequent measurements may need to be long to obtain an accurate representation of average glucose and reduce error. Using more than 100 days of steady glucose pattern for this method may reduce error. Additional length like 200 days or more or 300 days or more further reduces error.

[0055] Embodiments where one measured HbA1c value 102b can be used include a time period 106 about 100 days to about 300 days (or longer) with glucose levels being measured at least about 72 times per day (e.g., about every 20 minutes) to about 96 times per day (e.g., about every 15 minutes) or more often. Further, in such embodiments, the time between glucose level measurements may be somewhat consistent where an interval between two glucose level measurements should not be more than about an hour. Some missing data glucose measurements are tolerable when using only one measured HbA1c value. Increases in missing data may lead to more error.

[0056] Alternatively, in some instances where one measured HbA1c value 102b is used, the time period 106 may be shortened if a subject has an existing glucose level monitoring history with stable, consistent glucose profile. For example, for a subject who has been testing for a prolonged time (e.g., 6 months or longer) but, perhaps, at less frequent or regimented times, the existing glucose level measurements can be used to determine and analyze a glucose profile. Then, if more frequent and regimented glucose monitoring is performed over time period 106 (e.g., about 72 times to about 96 times or more per day over about 14 days or more) followed by measurement of HbA1c 102b and RPI 110b, the four sets of data in combination may be used to calculate one or more physiological parameters (k_{gly} , k_{age} , and/or K) at time point 101.

[0057] Alternatively, in some embodiments, one or more measured RPI values 110a, 110b, two measured HbA1c values (a first measured HbA1c value 102a at the beginning of a time period 106 and a second measured HbA1c value 102b at the end of the time period 106), and a plurality of glucose levels 104a measured during the time period 106 may be used to calculate one or more physiological parameters (k_{gly} , k_{age} , and/or K) at time point 101. In these embodiments, Equation 11 may be used to calculate k_{age} , and Equation 8 may be used to calculate k_{gly} and/or K at time point 101. In such embodiments, the plurality of glucose levels 104a may be measured for about 10 days to about 30 days or longer with measurements being, on average, about 4 times daily (e.g., about every 6 hours) to about 24 times daily (e.g., about every 1 hour) or more often.

[0058] In the foregoing embodiments, the RPI value(s) can be measured at a time other than as illustrated because measured RPI values are relatively stable over time. Therefore, the RPI value(s) can be measured at any time during time period 106 and be applicable to these embodiments.

[0059] The foregoing embodiments are not limited to the example glucose level measurement time period and frequency ranges provided. Glucose levels may be measured over a time period of about a few days to about 300 days or more (e.g., about one week or more, about 10 days or more, about 14 days or more, about 30 days or more, about 60 days or more, about 90 days or more, about 120 days or more, and so on). In some embodiments, the time period is 7 days or more, preferably one to ten months, and less than one year. The frequency of such glucose levels may be, on average, about 14,400 times daily (e.g., a time interval t_g of about every 6 seconds) (or more often) to about 3 times daily (e.g., a time interval t_g of about every 8 hours) (e.g., 1,440 times daily (e.g., a time interval t_g of about every minute), about 288 times daily (e.g., a time interval t_g of about every 5 minutes), about 144 times daily (e.g., a time interval t_g of about every 10 minutes), about 96 times daily (e.g., a time interval t_g of about every 15 minutes), about 72 times daily (e.g., a time interval t_g of about every 20 minutes), about 48 times daily (e.g., a time interval t_g of about every 30 minutes), about 24 times daily (e.g., a time interval t_g of about every 1 hour), about 12 times daily (e.g., a time interval t_g of about every 2 hours), about 8 times daily (e.g., a time interval t_g of about every 3 hours), about

6 times daily (e.g., a time interval t_g of about every 4 hours), about 4 times daily (e.g., a time interval t_g of about every 6 hours), and so on). In some instances, less frequent monitoring (like once or twice daily) may be used where the glucose measurements occur at about the same time (within about 30 minutes) daily to have a more direct comparison of day-to-day glucose levels and reduce error in subsequent analyses.

[0060] The foregoing embodiments may further include calculating an error or uncertainty associated with the one or more physiological parameters. In some embodiments, the error may be used to determine if another HbA1c value (not illustrated) should be measured near time point 101, if one or more glucose levels 104b should be measured (e.g., near time point 101), if the monitoring and analysis should be extended (e.g., to extend through time period 108 from time point 101 to time point 103 including measurement of glucose levels 104b during time period 108 and measurement of HbA1c value 102c at time point 103), and/or if the frequency of glucose level measurements 104b in an extended time period 108 should be increased relative to the frequency of glucose level measurements 104a during time period 106. In some embodiments, one or more of the foregoing actions may be taken when the error associated with k_{gly} , k_{age} , and/or K is at or greater than about 15%, preferably at or greater than about 10%, preferably at or greater than about 7%, and preferably at or greater than about 5%. When a subject has an existing disease condition (e.g., cardiovascular disease), a lower error may be preferred to have more stringent monitoring and less error in the analyses described herein.

[0061] Alternatively or when the error is acceptable, in some embodiments, one or more physiological parameters (k_{gly} , k_{age} , and/or K) at time point 101 may be used to determine one or more parameters or characteristics for a subject's personalized diabetes management (e.g., a cHbA1c at the end of time period 108, a personalized-target glucose range, and/or a treatment or change in treatment for the subject in the near future), each described in more detail further herein. In some instances, in addition to the foregoing embodiments, an HbA1c value may be measured at time point 103 and the one or more physiological parameters recalculated and applied to a future time period (not illustrated).

[0062] Alternatively or additionally, two values for k_{age} can be estimated using Equation 8 and Equation 11. A comparison of these two values can be used to determine if another HbA1c value (not illustrated) should be measured near time point 101, if one or more glucose levels 104b should be measured (e.g., near time point 101), if the monitoring and analysis should be extended (e.g., to extend through time period 108 from time point 101 to time point 103 including measurement of glucose levels 104b and measurement of HbA1c value 102c at time point 103), and/or if the frequency of glucose level measurements 104b in an extended time period 108 should be increased relative to the frequency of glucose level measurements 104a during time period 106. For example, if the two values of k_{age} are more than 10% different (e.g., the low value is not within 10% of the high value based on the high value), the individual's k_{mat} may be different than the typical k_{mat} (3.47 day^{-1}). If a large difference is observed (e.g., more than 20% difference), the individual's k_{mat} could be determined. If the individual's k_{mat} is stable over a time period (e.g., three to six months), the determined individual's k_{mat} should be used in place of the typical k_{mat} in Equation 11 in the methods, systems, and devices described herein. Fluctuation in k_{mat} could suggest other health problems.

[0063] The one or more physiological parameters and/or the one or more parameters or characteristics for a subject's personalized diabetes management can be measured and/or calculated for two or more times (e.g., time point 101 and time point 103) and compared. For example, k_{gly} at time point 101 and time point 103 may be compared. In another example, cHbA1c at time point 103 and at a future time may be compared. Some embodiments, described further herein, may use such comparisons to (1) monitor progress and/or effectiveness of a subject's personalized diabetes management and, optionally, alter the subject's personalized diabetes management, (2) identify an abnormal or diseased physiological condition, and/or (3) identify subjects taking supplements and/or medicines that affect red blood cell production and/or affect metabolism.

[0064] Each of the example methods, devices, and systems described herein can utilize the one or more physiological parameters (k_{gly} , k_{age} , and K) and perform one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like). The one or more physiological

parameters (k_{gly} , k_{age} , and K) and related analyses may be updated periodically (e.g., about every 3 months to annually). The frequency of updates may depend on, among other things, the subject's glucose level and diabetes history (e.g., how well the subject stays within the prescribed thresholds), other medical conditions, and the like.

Other Factors

[0065] In the embodiments described herein that apply the one or more physiological parameters (k_{gly} , k_{age} , and/or K), one or more other subject-specific parameters may be used in addition to the one or more physiological parameters. Examples of subject-specific parameters may include, but are not limited to, vital information (e.g., heart rate, body temperature, blood pressure, or any other vital information), body chemistry information (e.g., drug concentration, blood levels, troponin level, cholesterol level, or any other body chemistry information), meal data/information (e.g., carbohydrate amount, sugar amount, or any other information about a meal), activity information (e.g., the occurrence and/or duration of sleep and/or exercise), an existing medical condition (e.g., cardiovascular disease, heart valve replacement, cancer, and systemic disorder such as autoimmune disease, hormone disorders, and blood cell disorders), a family history of a medical condition, a current treatment, an age, a race, a gender, a geographic location (e.g., where a subject grew up or where a subject currently lives), a diabetes type, a duration of diabetes diagnosis, and the like, and any combination thereof.

Systems

[0066] In some embodiments, determining the one or more physiological parameters (k_{gly} , k_{age} , and/or K) for a subject may be performed using a physiological parameter analysis system.

[0067] FIG. 2 illustrates an example of a physiological parameter analysis system 211 for providing physiological parameter analysis in accordance with some of the embodiments of the present disclosure. The physiological parameter analysis system 211 includes one or more processors 212 and one or more machine-readable storage media 214. The one or more machine-readable storage media 214 contains

a set of instructions for performing a physiological parameter analysis routine, which are executed by the one or more processors 212.

[0068] In some embodiments, the instructions include receiving inputs 216 (e.g., one or more RPI values, one or more glucose levels, one or more HbA1c levels, one or more physiological parameters (k_{gly} , k_{age} , and/or K) previously determined, or more other subject-specific parameters, and/or one or more times associated with any of the foregoing), determining outputs 218 (e.g., one or more physiological parameters (k_{gly} , k_{age} , and/or K), an error associated with the one or more physiological parameters, one or more parameters or characteristics for a subject's personalized diabetes management (e.g., cHbA1c, a personalized-target glucose range, an average-target glucose level, a supplement or medication dosage, among other parameters or characteristics), a matched group of participants, and the like), and communicating the outputs 218. In some embodiments, communication of the inputs 216 may be via a user-interface (which may be part of a display), a data network, a server/cloud, another device, a computer, or any combination thereof, for example. In some embodiments, communication of the outputs 218 may be to a display (which may be part of a user-interface), a data network, a server/cloud, another device, a computer, or any combination thereof, for example.

[0069] A "machine-readable medium", as the term is used herein, includes any mechanism that can store information in a form accessible by a machine (a machine may be, for example, a computer, network device, cellular phone, personal digital assistant (PDA), manufacturing tool, any device with one or more processors, and the like). For example, a machine-accessible medium includes recordable/non-recordable media (e.g., read-only memory (ROM), random access memory (RAM), magnetic disk storage media, optical storage media, flash memory devices, and the like).

[0070] In some instances, the one or more processors 212 and the one or more machine-readable storage media 214 may be in a single device (e.g., a computer, network device, cellular phone, PDA, an analyte monitor, and the like).

[0071] In some embodiments, a physiological parameter analysis system may include other components. FIG. 3 illustrates another example of a physiological

parameter analysis system 311 for providing physiological parameter analysis in accordance with some of the embodiments of the present disclosure.

[0072] The physiological parameter analysis system 311 includes health monitoring device 320 with subject interface 320A and analysis module 320B. The health monitoring device 320 is, or may be, operatively coupled to data network 322. Also provided in physiological parameter analysis system 311 is a glucose monitor 324 (e.g., in vivo and/or in vitro (ex vivo) devices or system) and a data processing terminal/personal computer (PC) 326, each operatively coupled to health monitoring device 320 and/or data network 322. Further shown in FIG. 3 is server/cloud 328 operatively coupled to data network 322 for bi-directional data communication with one or more of health monitoring device 320, data processing terminal/PC 326 and glucose monitor 324. Physiological parameter analysis system 311 within the scope of the present disclosure can exclude one or more of server/cloud 328, data processing terminal/PC 326 and/or data network 322.

[0073] In certain embodiments, analysis module 320B is programmed or configured to perform physiological parameter analysis and, optionally, other analyses (e.g., cHbA1c, personalized target glucose range, and others described herein). As illustrated, analysis module 320B is a portion of the health monitoring device 320 (e.g., executed by a processor therein). However, the analysis module 320B may alternatively be associated with one or more of server/cloud 328, glucose monitor 324, and/or data processing terminal/PC 326. For example, one or more of server/cloud 328, glucose monitor 324, and/or data processing terminal/PC 326 may comprise a machine-readable storage medium (or media) with a set of instructions that cause one or more processors to execute the set of instructions corresponding to the analysis module 320B.

[0074] While the health monitoring device 320, the data processing terminal/PC 326, and the glucose monitor 324 are illustrated as each operatively coupled to the data network 322 for communication to/from the server/cloud 328, one or more of the health monitoring device 320, the data processing terminal/PC 326, and the glucose monitor 324 can be programmed or configured to directly communicate with the server/cloud 328, bypassing the data network 322. The mode of communication between the health monitoring device 320, the data processing

terminal/PC 326, the glucose monitor 324, and the data network 322 includes one or more wireless communication, wired communication, RF communication, BLUETOOTH® communication, WiFi data communication, radio frequency identification (RFID) enabled communication, ZIGBEE® communication, or any other suitable data communication protocol, and that optionally supports data encryption/decryption, data compression, data decompression and the like.

[0075] As described in further detail below, the physiological parameter analysis can be performed by one or more of the health monitoring device 320, data processing terminal/PC 326, glucose monitor 324, and server/cloud 328, with the resulting analysis output shared in the physiological parameter analysis system 311.

[0076] Additionally, while the glucose monitor 324, the health monitoring device 320, and the data processing terminal/PC 326 are illustrated as each operatively coupled to each other via communication links, they can be modules within one integrated device (e.g., sensor with a processor and communication interface for transmitting/receiving and processing data).

Measuring Glucose and HbA1c Levels

[0077] The measurement of the plurality of glucose levels through the various time periods described herein may be done with in vivo and/or in vitro (ex vivo) methods, devices, or systems for measuring at least one analyte, such as glucose, in a bodily fluid such as in blood, interstitial fluid (ISF), subcutaneous fluid, dermal fluid, sweat, tears, saliva, or other biological fluid. In some instances, in vivo and in vitro methods, devices, or systems may be used in combination.

[0078] Examples of in vivo methods, devices, or systems measure glucose levels and optionally other analytes in blood or ISF where at least a portion of a sensor and/or sensor control device is, or can be, positioned in a subject's body (e.g., below a skin surface of a subject). Examples of devices include, but are not limited to, continuous analyte monitoring devices and flash analyte monitoring devices. Specific devices or systems are described further herein and can be found in U.S. Patent No. 6,175,752 and U.S. Patent Application Publication No. 2011/0213225, the entire disclosures of each of which are incorporated herein by reference for all purposes.

[0079] In vitro methods, devices, or systems (including those that are entirely non-invasive) include sensors that contact the bodily fluid outside the body for measuring glucose levels. For example, an in vitro system may use a meter device that has a port for receiving an analyte test strip carrying bodily fluid of the subject, which can be analyzed to determine the subject's glucose level in the bodily fluid. Additional devices and systems are described further below.

[0080] As described above the frequency and duration of measuring the glucose levels may vary from, on average, about 3 times daily (e.g., about every 8 hours) to about 14,400 times daily (e.g., about every 10 seconds) (or more often) and from about a few days to over about 300 days, respectively.

[0081] Once glucose levels are measured, the glucose levels may be used to determine the one or more physiological parameters (k_{gly} , k_{age} , and/or K) and, in some instances, other analyses (e.g., cHbA1c, personalized target glucose range, and others described herein). In some instances, such analyses may be performed with a physiological parameter analysis system. For example, referring back to FIG. 3, in some embodiments, the glucose monitor 324 may comprise a glucose sensor coupled to electronics for (1) processing signals from the glucose sensor and (2) communicating the processed glucose signals to one or more of health monitoring device 320, server/cloud 328, and data processing terminal/PC 326.

[0082] The measurement of one or more HbA1c levels at the various times described herein may be according to any suitable method. Typically, HbA1c levels are measured in a laboratory using a blood sample from a subject. Examples of laboratory tests include, but are not limited to, a chromatography-based assay, an antibody-based immunoassay, and an enzyme-based immunoassay. HbA1c levels may also be measured using electrochemical biosensors.

[0083] The frequency of HbA1c level measurements may vary from, on average, monthly to annually (or less often if the average glucose level of the subject is stable).

[0084] Referring back to FIG. 3, in some embodiments, HbA1c levels may be measured with a laboratory test where the results are input to the server/cloud 328, the subject interface 320A, and/or a display from the testing entity, a medical professional, the subject, or other user. Then, the HbA1c levels may be received by

the one or more of health monitoring device 320, server/cloud 328, and data processing terminal/PC 326 for analysis by one or more methods described herein.

Calculated HbA1c (cHbA1c)

[0085] After one or more physiological parameters (k_{gly} , k_{age} , and/or K) are calculated, a plurality of glucose measurements may be taken for a following time period and used for calculating HbA1c during and/or at the end of the following time period. For example, referring back to FIG. 1, one or more physiological parameters (k_{gly} , k_{age} , and/or K) may be calculated at time point 101 based on one or more measured RPI values 110a, 110b, measurements of the plurality of glucose levels 104a over time period 106, a measured HbA1c level 102b at the end of time period 106, and optionally a measured HbA1c level 102a at the beginning of time period 106. Then, for a subsequent time period 108, a plurality of glucose levels 104b may be measured. Then, during and/or at the end of the time period 108, Equation 8 can be used to determine a cHbA1c value ($HbA1c_z$ of Equation 8) where $HbA1c_0$ is the measured HbA1c level 102b at the end of time period 106 (which is the beginning of time period 108), $[G_i]$ are the glucose levels or averaged glucose levels during time period 108 (or the portion of time period 108 where cHbA1c is determined during the time period 108), and the provided one or more physiological parameters (k_{gly} , k_{age} , and/or K) corresponding to time point 101 are used.

[0086] A subject's cHbA1c may be determined for several successive time periods based on the one or more physiological parameters (k_{gly} , k_{age} , and/or K) determined with the most recently measured HbA1c level, the most recently measured RPI value(s), and the intervening measurements of glucose levels. The RPI value may be measured periodically (e.g., every 6 months to a year) to recalculate k_{age} . The most recent RPI value or an average of two or more RPI values can be used in the calculation. The HbA1c may be measured periodically (e.g., every 6 months to a year) to recalculate the one or more physiological parameters. The time between remeasuring the RPI value and the measured HbA1c may depend on (1) the consistency of the measurements of glucose levels, (2) the frequency of the measurements of glucose levels, (3) a subject's and corresponding family's diabetic history, (4) the length of time the subject has been diagnosed with diabetes, (5)

changes to a subject's personalized diabetes management (e.g., changes in medications/dosages, changes in diet, changes in exercise, and the like), (6) the presence of a disease or disorder that effects k_{mat} (e.g., anemia, a bone marrow disease, a genetic condition, an immune system disorder, and combinations thereof). For example, a subject with consistent measurements of glucose levels (e.g., a [G] with less than 5% variation) and frequent measurements of glucose levels (e.g., continuous glucose monitoring) may measure HbA1c levels less frequently than a subject who recently (e.g., within the last 6 months) changed the dosage of a glycation medication, even with consistent and frequent measurements of glucose levels.

[0087] FIG. 4, with reference to FIG. 2, illustrates an example of a cHbA1c report that may be generated as an output 218 by a physiological parameter analysis system 211 of the present disclosure. The illustrated example report includes a plot of average glucose level over time. Also included on the report are the most recently measured RPI value (open circle), the most recently measured HbA1c level (cross), and cHbA1c levels (asterisks) calculated by the physiological parameter analysis system 211. While the most recently measured RPI value and the most recently measured HbA1c level are illustrated as being measured on different days, the two measurements can be done in the same visit to a health care provider.

[0088] Two cHbA1c levels are illustrated, but one or more cHbA1c levels may be displayed on the report, including a line that continuously tracks cHbA1c. Alternatively, the output 218 of the physiological parameter analysis system 211 may include a single number for a current or most recently calculated cHbA1c, a table corresponding to the data of FIG. 4, or any other report that provides a subject, healthcare provider, or the like with at least one cHbA1c level.

[0089] In some instances, the cHbA1c may be compared to a previous cHbA1c and/or a previous measured HbA1c level to monitor the efficacy of a subject's personalized diabetes management. For example, if a diet and/or exercise plan is being implemented as part of a subject's personalized diabetes management, with all other factors (e.g., medication and other diseases) equal, then changes in the cHbA1c compared to the previous cHbA1c and/or the previous measured HbA1c level

may indicate if the diet and/or exercise plan is effective, ineffective, or a gradation therebetween.

[0090] In some instances, the cHbA1c may be compared to a previous cHbA1c and/or a previous measured HbA1c level to determine if another HbA1c measurement should be taken. For example, in the absence of significant glucose profile change, if the cHbA1c changes by 0.5 percentage units or more (e.g., changes from 7.0% to 6.5% or from 7.5% to 6.8%) as compared to the previous cHbA1c and/or the previous measured HbA1c level, another measured HbA1c level may be tested.

[0091] In some instances, a comparison of the cHbA1c to a previous cHbA1c and/or a previous measured HbA1c level may indicate if an abnormal or diseased physiological condition is present. For example, if a subject has maintained a cHbA1c and/or measured HbA1c level for an extended period of time, then if a change in cHbA1c is identified with no other obvious causes, the subject may have a new abnormal or diseased physiological condition. Indications of what that new abnormal or diseased physiological condition may be gleaned from the one or more physiological parameters (k_{gly} , k_{age} , and/or K). Details of abnormal or diseased physiological conditions relative to the one or more physiological parameters are discussed further herein.

Personalized-Target Glucose Range

[0092] Typically, the glucose levels in subjects with diabetes are preferably maintained between 54 mg/dL and 180 mg/dL. However, the kinetic model described herein (see Equation 6) illustrates that intracellular glucose levels are dependent on physiological parameters k_{gly} , k_{age} , and K . Therefore, a measured glucose level may not correspond to the actual physiological conditions in a subject. For example, a subject with a higher than normal K may glycate glucose more readily. Therefore, a 180 mg/dL measured glucose level may be too high for the subject and, in the long run, potentially worsen the effects of the subject's diabetes. In another example, a subject with a lower than normal k_{gly} may glycate glucose to a lesser degree. Accordingly, at a 54 mg/dL glucose level, the subject's intracellular glucose level may

be much lower making the subject feel weak and, in the long term, lead to the subject being hypoglycemic.

[0093] Using the accepted normal lower glucose limit (LGL) and the accepted normal HbA1c upper limit (AU), equations for a personalized lower glucose limit (GL) (Equation 13) and a personalized upper glucose limit (GU) (Equation 14) can be derived from Equation 6.

$$GL = (LGL * k_{gly}^{ref}) / k_{gly}^{sub} \tag{Equation 13}$$

where k_{gly}^{ref} is the k_{gly} for a normal person and k_{gly}^{sub} is the subject's k_{gly} .

$$GU = AU / (K(1 - AU)) \tag{Equation 14}$$

[0094] Equation 13 is based on k_{gly} because the lower limit of a glucose range is based on an equivalent intracellular glucose level. Equation 14 is based on K because the upper limit of a glucose range is based on an equivalent extracellular glucose level (e.g., the accepted normal HbA1c upper limit).

[0095] The currently accepted values for the foregoing are LGL=54 mg/dL, $k_{gly}^{ref}=6.2*10^{-6} \text{ dL*mg}^{-1}\text{*day}^{-1}$, and AU=0.08 (i.e., 8%). Using the currently accepted values Equations 15 and 16 can be derived.

$$GL = 3.35 * 10^{-4} \text{ day}^{-1} / k_{gly}^{sub} \tag{Equation 15}$$

$$GU = 0.087 / K \tag{Equation 16}$$

[0096] FIG. 5A illustrates an example of a method of determining a personalized-target glucose range 530. A desired intracellular glucose range 532 (e.g., the currently accepted glucose range) having a lower limit 534 and an upper limit 536 can be personalized using one or more determined physiological parameters (k_{gly} , k_{age} , and/or K) 538 using Equation 13 and Equation 14, respectively. This results in a personalized lower glucose limit (GL) 540 (Equation 13 \pm 7%) and a personalized upper glucose limit (GU) 542 (Equation 14 \pm 7%) that define the personalized-target

glucose range 530. After one or more physiological parameters (k_{gly} , k_{age} , and/or K) are calculated, a personalized-target glucose range may be determined where the lower glucose limit may be altered according to Equation 13 (or Equation 15) $\pm 7\%$ and/or the upper glucose limit may be altered according to Equation 14 (or Equation 16) $\pm 7\%$. The $\pm 7\%$ relative to each of the foregoing calculated values allows for a different value that is substantially close to the calculated value to be used, so that the personalized nature of the personalized-target glucose range 530 is maintained. Alternatively, the $\pm 7\%$ can be $\pm 10\%$, $\pm 5\%$, or $\pm 3\%$.

[0097] For example, a subject with a K of $4.5 \cdot 10^{-4}$ dL/mg and a k_{gly} of $7.0 \cdot 10^{-6}$ dL*mg⁻¹*day⁻¹ may have a personalized-target glucose range of about 48 ± 3.4 mg/dL to about 193 ± 13.5 mg/dL. Therefore, the subject may have a wider range of acceptable glucose levels than the currently practiced glucose range.

[0098] FIG. 5B, with reference to FIG. 2, illustrates an example of a personalized-target glucose range report that may be generated as an output 218 by a physiological parameter analysis system 211 of the present disclosure. The illustrated example report includes a plot of glucose level over a day relative to the foregoing personalized-target glucose range (area between the dashed lines). Alternatively, other reports may include, but are not limited to, an ambulatory glucose profile (AGP) plot, a numeric display of the personalized-target glucose range with the most recent glucose level measurement, and the like, and any combination thereof.

[0099] In another example, a subject with a K of $6.5 \cdot 10^{-4}$ dL/mg and a k_{gly} of $6.0 \cdot 10^{-6}$ dL*mg⁻¹*day⁻¹ may have a personalized-target glucose range of about 56 ± 3.5 mg/dL to about 134 ± 10 mg/dL. With the much-reduced upper glucose level limit, the subject's personalized diabetes management may include more frequent glucose level measurements and/or medications to stay substantially within the personalized-target glucose range.

[0100] In yet another example, a subject with a K of $5.0 \cdot 10^{-4}$ dL/mg and a k_{gly} of $5.0 \cdot 10^{-6}$ dL*mg⁻¹*day⁻¹ may have a personalized-target glucose range of about 67 ± 4.5 mg/dL to about 174 ± 12 mg/dL. This subject is more sensitive to lower glucose levels and may feel weak, hungry, dizzy, etc. more often if the currently practiced glucose range (54 mg/dL and 180 mg/dL) were used.

[0101] While the foregoing examples all include a personalized glucose lower limit and a personalized glucose upper limit, a personalized-target glucose range may alternatively include only the personalized glucose lower limit or the personalized glucose upper limit and use the currently practiced glucose lower or upper limit as the other value in the personalized-target glucose range.

[0102] The personalized-target glucose range may be determined and/or implemented in a physiological parameter analysis system. For example, a set of instructions or program associated with a glucose monitor and/or health monitoring device that determines a therapy (e.g., an insulin dosage) may use a personalized-target glucose range in such analysis. In some instances, a display or subject interface with display may display the personalized-target glucose range.

[0103] The personalized-target glucose range may be updated over time as one or more physiological parameters are recalculated.

Personalized-Target Average Glucose

[0104] In some instances, a subject's personalized diabetes management may include having an HbA1c value target for a future time point. For example, referring to FIG. 1, a subject may have a measured RPI value 110b and a measured HbA1c value 102b for time point 101 and a plurality of glucose level measurements prior thereto over time period 106. The subject's personalized diabetes management may include a target HbA1c value (AT) for time point 103 that would correlate to improved health for the subject. Equation 17 can be used to calculate a personalized-target average glucose level (GT) for the next time period 108 and be based on the target HbA1c value (AT) and the subject's K calculated at time point 101.

$$GT = AT / (K(1 - AT)) \quad \text{Equation 17}$$

[0105] In some embodiments, a physiological parameter analysis system may determine an average glucose level for the subject during time period 108 and, in some instances, display the average glucose level and/or the target average glucose level. The subject may use the current average glucose level and the target average glucose level to self-monitor their progress over time period 108. In some

instances, the current average glucose level may be transmitted (periodically or regularly) to a health care provider using a physiological parameter analysis system for monitoring and/or analysis.

[0106] FIG. 6, with reference to FIG. 2, illustrates an example of a personalized-target average glucose report that may be generated as an output 218 by a physiological parameter analysis system 211 of the present disclosure. The illustrated example report includes a plot of a subject's average glucose (solid line) over time and the personalized-target average glucose (illustrated at 150 mg/dL, dashed line). Alternatively, other reports may include, but are not limited to, a numeric display of the personalized-target average glucose with the subject's average glucose level over a given time frame (e.g., the last 12 hours), and the like, and any combination thereof.

[0107] The personalized-target average glucose may be updated over time as one or more physiological parameters are recalculated.

Personalized Treatment - Subject Triage

[0108] Insulin pumps along with continuous glucose monitoring may be used for subjects that need tight control of their glucose levels. As illustrated above, the target glucose range is individualized and based on k_{gly} and/or K . Therefore, in some instances, subjects with a narrower personalize-target glucose range may be stronger candidates for insulin pumps with continuous monitoring. Triage of subjects to be stronger candidates for insulin pumps along with continuous glucose monitoring may be based on a spread of the personalized-target glucose range, k_{gly} , and/or K .

[0109] The spread between currently practiced glucose lower or upper limit is about 126 mg/dL. However, as illustrated above, depending on k_{gly} and K that could narrow to about 78 mg/dL. Some embodiments may involve triaging a subject to an insulin pump with continuous glucose monitoring when the personalized-target glucose range span is about 110 mg/dL or less, preferably about 100 mg/dL or less.

[0110] Some embodiments may involve triaging a subject to an insulin pump with continuous glucose monitoring when k_{gly} is 6.4×10^{-6} dL*mg⁻¹*day⁻¹ or less, when k_{gly} is 6.0×10^{-6} dL*mg⁻¹*day⁻¹ or less, when k_{gly} is 5.5×10^{-6} dL*mg⁻¹*day⁻¹ or less, or when k_{gly} is 5.0×10^{-6} dL*mg⁻¹*day⁻¹.

[0111] Some embodiments may involve triaging a subject to an insulin pump with continuous glucose monitoring when K is 5.0×10^{-4} dL/mg or greater, when K is 5.5×10^{-4} dL/mg or greater, when K is 5.75×10^{-4} dL/mg or greater, or when K is 6.0×10^{-4} dL/mg or greater.

[0112] In some embodiments, triaging a subject to an insulin pump with continuous glucose monitoring may be a stepped triage where first a subject's glucose levels are monitored continuously for a reasonable time period (e.g., about 5 days, about 10 days, about 15 days, about 30 days, or more). This continuous monitoring time period can be used to assess if the subject is capable of managing glucose levels effectively or if an insulin pump is better, or required.

[0113] Whether the triaging is straight to an insulin pump with continuous glucose monitoring or a stepped triage with monitoring before treatment with the insulin pump may be determined by the level of the indicators (i.e., the personalized-target glucose range span, k_{gly} , K , or any combination thereof). For example, if k_{gly} is about 6.4×10^{-6} dL*mg⁻¹*day⁻¹ but the personalized-target glucose range span is about 100 mg/dL, the subject may be more suited for a stepped triage as compared to another subject where the corresponding indicators suggest an insulin pump should be used.

[0114] In some embodiments, triage may be based on a lookup table (e.g., stored in a physiological parameter analysis system of the present disclosure). The lookup table may, for example, correlate multiple values to each other including, but not limited to, one or more physiological parameters (k_{gly} , k_{age} , and/or K), a personalized-target glucose range span, and/or other factors described herein like an existing medical condition, a family history of a medical condition, a current treatment, an age, a race, a gender, a geographic location, a diabetes type, a duration of diabetes diagnosis, and the like, and any combination thereof. Columns in the lookup table may, for example, define ranges or limits for the foregoing parameters, and the rows may indicate a suggested course of action, which may be an output 218 of a physiological parameter analysis system 211 of FIG. 2. For example, two columns may define an upper and lower bound of k_{gly} , where each row corresponds to a suggested course of action, such as "candidate for insulin pump," "candidate for closed-loop control system," "candidate for basal/bolus insulin

therapy," "candidate for basal only insulin therapy," or any such treatment used to control diabetes or affect the subject's glycation. In some instances, more than one course of action may be indicated. Therefore, in this example, a subject triage report may simply display the suggested course(s) of action.

[0115] Alternatively, the subject triage report may, for example, show a map of zones corresponding to the course(s) of action on a plot defined by one or more of the parameters described above relative to the lookup table. Such zones may, in some instances, be defined by the lookup table. Each zone on the map may be labeled as representing a recommendation and the glyceic parameter point for the subject may be indicated on the map to show the relevant zone for that subject.

[0116] While the two foregoing subject triage reports are examples based on lookup tables, alternatively, the two foregoing subject triage reports could be based on other correlations (e.g., a mathematical algorithm or matrix analysis) between (1) one or more physiological parameters (k_{gly} , k_{age} , and/or K), a personalized-target glucose range span, and/or other factors described herein and (2) a course(s) of action.

[0117] As described, a subject's glycation parameters may help healthcare providers and payors to better determine what therapy tools are most appropriate for which subjects. For instance, closed-loop insulin pump systems are expensive to employ and maintain, but subjects who have a high glycation rate may have a very narrow personalized-target glucose range where the safest treatment is keeping their glucose levels within such ranges using a closed-loop insulin pump system.

[0118] In some embodiments, the insulin pumps along with continuous glucose monitoring may be closed-loop systems. In some embodiments, the insulin pumps along with continuous glucose monitoring may be hybrid-loop systems. For example, referring back to FIG. 3, a physiological parameter analysis system may further include one of the foregoing insulin pumps in communication with one or more of the components in the physiological parameter analysis system 311, for example, the glucose monitor 324 (e.g., a continuous glucose monitoring system) and health monitoring device 320.

Personalized Treatment - Titration of Diabetes Medication

[0119] In some embodiments, one or more physiological parameters (k_{gly} , k_{age} , and K) may be used in titrating dosages of diabetes medication (e.g., insulin) given to a subject. For example, referring to FIG. 2, a physiological parameter analysis system 211 of the present disclosure may determine or have input (1) one or more physiological parameters, (2) a personalized-target glucose range, and/or (3) a personalized-target average glucose. Then, when a subsequent glucose level is measured the physiological parameter analysis system 211 may output a recommended diabetes medication dosage. An alternative or complimentary output 218 may be a glucose pattern insight report.

[0120] Examples of glucose pattern insight reports can be found in U.S. Patent Application Publication Nos. 2014/0188400 and 2014/0350369, the entire disclosures of each of which are incorporated herein by reference for all purposes. The disclosed analyses and reports in the forgoing applications may be modified based on the one or more physiological parameters (k_{gly} , k_{age} , and K) of the present disclosure.

[0121] For example, FIG. 7, with reference to FIG. 2, illustrates an example of a glucose pattern insight report that may be an output 218 of a physiological parameter analysis system 211 (e.g., an insulin titration system). The illustrated glucose pattern insights report incorporates an AGP along with a table of glycemic control measures (or "traffic lights"). As illustrated, the report includes an AGP plot over an analysis time period (e.g., about one to about four months) that illustrates the personalized-target average glucose at 120 mg/dL, the average glucose levels for the subject over the analysis time period, the 25th to 75th percentile of glucose levels for the subject over the analysis time period, and the 10th to 90th percentile of glucose levels for the subject over the analysis time period. The glucose pattern insight report may further or alternatively display the personalized-target glucose range. Additionally, the glucose pattern insight report may optionally further include one or more of: a measured HbA1c level, a cHbA1c level, the date range over which the average glucose and related percentiles were determined, and the like.

[0122] Below the AGP plot on the glucose pattern insight report is the table that correlates one or more (illustrated as three) glycemic control measures to a

subject's average glucose levels for a given shortened time period of the day over the analysis time period. The correlation displays, in this example, as traffic lights (e.g., green (good), yellow (moderate), or high (red)) that correspond to the risk of a condition based on the glycemic control measures. Examples of glycemic control measures include, but are not limited to, likelihood of low glucose, likelihood of high glucose, the proximity of the average glucose to the personalized-target average glucose, the adherence of the glucose levels to the personalized-target glucose range, the degree of variability of the average glucose below (or above) the personalized-target average glucose, the degree of variability of the glucose levels outside (below and/or above) the personalized-target glucose range, and the like.

[0123] In some embodiments, the glucose pattern insights report may be used as part of a diabetes medication titration system, where the traffic lights (or values associated therewith) can drive logic to provide treatment modifications such as changing basal dosages of the diabetes medication or bolus amounts of the diabetes medication associated with meals. For example, when used in conjunction with an automatic or semi-automatic system for titration, the logic driven by these traffic lights may provide recommendations to subjects on dosage adjustments.

[0124] The glucose pattern insights report and related analyses that incorporate the use of the kinetic model described herein may provide better treatment to subjects with diabetes. For this example, as described above, a subject with a K of 5.0×10^{-4} dL/mg and a k_{gly} of 5.0×10^{-6} dL*mg⁻¹*day⁻¹ may have a personalized-target glucose range of about 67 ± 4.5 mg/dL to about 174 ± 12 mg/dL. This subject is more sensitive to lower glucose levels and may feel weak, hungry, dizzy, etc. more often if the currently practiced glucose range (54 mg/dL and 180 mg/dL) were used. The analytical logic used for the glucose pattern insights report described herein that uses one or more physiological parameters (k_{gly} , k_{age} , and K) may include settings that define the risk of hypoglycemia as traffic lights for "likelihood of low glucose." For example, if the likelihood of low glucose indicates low risk (e.g., a green traffic light), then it is considered safe to increase insulin. If the likelihood of low glucose indicates moderate risk (e.g., yellow traffic light), then it is considered that the current risk is acceptable but no further increase of insulin should be made. Finally, if the likelihood of low glucose indicates high risk, then it is

recommended that insulin should be reduced to get the glucose back to tolerable levels. For a subject with high risk of hypoglycemia because of an increased lower glucose level threshold, the threshold glucose values at which moderate and high risk are indicated (e.g., how far below the lower glucose level threshold) may be higher than for a subject with a normal lower glucose level threshold.

[0125] While the foregoing example discusses a glucose pattern insights report as the output 218, other outputs using the same logic and analyses may be used in other embodiments. For example, the output 218 may be values of dosage recommendations.

[0126] The one or more physiological parameters (k_{gly} , k_{age} , and K) and related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c , and the like) may be updated periodically (e.g., about every 3 months to annually). The frequency of updates may depend on, among other things, the subject's glucose level and diabetes history (e.g., how well the subject stays within the prescribed thresholds), other medical conditions, and the like.

[0127] An insulin titration system may also utilize error associated with the one or more physiological parameters (k_{gly} , k_{age} , and K). Error values can be determined using standard statistical techniques by those skilled in the art and may be used as another set of parameters for configuring the titration system. For example, the titration system may use the reduced amount of acceptable risk for hypoglycemia (i.e., a smaller tolerance to be below the lower glucose level threshold for indicating moderate and high risk) when the lower glucose level of the personalized-target glucose range is about 64 mg/dL with an error of about 7% or less.

[0128] The dosage of diabetes medication (e.g., via titration) may be updated over time as one or more physiological parameters are recalculated.

Closed-Loop and Hybrid Closed-Loop Control Systems

[0129] Closed-loop systems and hybrid closed-loop systems that recommend or administer insulin dosages to a subject have been developed for insulin delivery based on near real-time glucose readings. These systems are often based on models describing the subject's physiology, glucose sensor dynamics, and

glucose sensor error characteristics. In some embodiments, the one or more physiological parameters (k_{gly} , k_{age} , and K) and related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) may be incorporated into the closed-loop system, similarly to what was described above for insulin titration, in order to better meet the needs of the subject.

[0130] Closed-loop systems often are configured to “drive” the subject’s glucose levels inside a target range and/or toward a single glucose target, which may be the personalized-target glucose range and/or the personalized-target average glucose described herein. For example, for subjects with high k_{gly} and an increased lower glucose limit for their personalized-target glucose range, the controller may drive their glucose levels in a way to stay above the lower glucose limit based on k_{gly} , which avoids lower glucose levels that adversely affect them more than subjects with a normal glucose range. Similarly, subjects with reduced upper glucose limits for their personalized-target glucose range may have the controller of a closed-loop insulin delivery system and hybrid closed-loop insulin delivery system drive glucose to stay below the personalized-upper glucose limit to mitigate hyperglycemic effects.

[0131] The metrics by which a closed-loop insulin delivery system and hybrid closed-loop insulin delivery system determine a dosage of insulin may be updated over time as one or more physiological parameters are recalculated. For example, the personalized-target glucose range and/or personalized-target average glucose may be updated when one or more physiological parameters are recalculated.

Personalized Treatment - Glycation Medication

[0132] Diabetes is a disease caused by a subject’s pancreas being unable to produce sufficient (or any) insulin. However, in some instances, a subject’s glycation process may be the source of the body not properly controlling intracellular glucose. Such subjects may be more responsive to treatments that use glycation medications rather than traditional diabetes treatments. The kinetic model of the present disclosure derives k_{gly} and/or K (which is based in part on k_{gly}). Therefore, one or both of these physiological parameters may be used in identifying, treating, and/or monitoring a subject with a glycation disorder.

[0133] Some embodiments may involve monitoring k_{gly} and/or K for a subject on glycation medication and, in some instances, changing a glycation medication dosage based on changes to k_{gly} and/or K . For example, referring to FIG. 1, some embodiments may involve determining k_{gly1} and/or K_1 at a time point 101 and a corresponding k_{gly2} and/or K_2 at time point 103 (as described above) and treating a subject with glycation medication over time period 108. Then, based on a comparison of k_{gly1} and/or K_1 to the corresponding k_{gly2} and/or K_2 , a dosage and/or type of glycation medication may be altered for a subsequent time period. Then, in some instances, a corresponding k_{gly3} and/or K_3 may be determined at the end of the subsequent time period for comparison to one or more of the previously determined physiological parameters. The time between time point 101 and time point 103 and between time point 103 and the time point corresponding to k_{gly3} and/or K_3 should be at least the expected time for the glycation medication to make a measurable change in the parameter being monitored, which may depend on the medication and the dosage.

[0134] In some embodiments, an output 218 of the physiological parameter analysis system 211 of FIG. 2 may be a glycation medication report that includes glycation medication and/or dosage recommendations based on k_{gly} and/or K calculated by the physiological parameter analysis system 211. This output 218 may be displayed for a subject, healthcare provider, and/or the like to review and adjust the glycation medication and/or dosage.

[0135] Alternatively, the dosage recommendations provide a subject and/or automated medication delivery system with the next dosage to be administered. Here, the system guides titration of the medication, where the subject may start with the lowest dosage or a recommended initial dosage. The initial dosage may be defined by the current condition of the subject, the subject's k_{gly1} and/or K_1 , and other factors described herein. After an appropriate amount of time has passed for the effects of the current medication dosage to be adequately determined, k_{gly2} and/or K_2 can be determined based on a new measured HbA1c level and the glucose levels measured during the medication dosage. k_{gly2} and/or K_2 may then be compared to (1) k_{gly1} and/or K_1 and/or (2) a target k_{gly} and/or a target K to determine if the dosage needs to be changed. For example, for a high glycation subject taking a medication that is

intended to lower glycation rate, if k_{gly2} is still higher than desired, then the dosage recommendation may be increased according to (1) standard titration protocols and/or (2) a system that accounts for how past dosage changes affect the subject (known as control theory). In another example, if the subject's k_{gly2} is low, then the dosage may be decreased. Medications could also be similarly titrated to affect K or other parameters. In addition, a similar process could be used to recommend non-medication treatments such as blood transfusion or harvesting by guiding the appropriate amount of blood to be affected.

[0136] Using k_{gly} and/or K to monitor glycation medication efficacy and titration is valuable to healthcare providers for treating subjects with abnormal glycation physiology.

[0137] The metrics by which a dosage of glycation medication is determined may be updated over time as one or more physiological parameters are recalculated.

Identifying Abnormal or Diseased Physiological Condition

[0138] The kinetic modeling, in certain embodiments, provides physiological parameters (e.g., k_{gly} , k_{age} (or k_{gen}), and/or K) for different time periods, where the same parameter is compared between the different time periods to indicate abnormal or disease state of the subject. Variation in the k_{gly} , k_{age} , and/or K in subjects may provide an indication of abnormal or disease condition of the subject. That is, while k_{gly} , k_{age} , and/or K varies between subjects, a variation in k_{gly} , k_{age} , and/or K for a single individual are small and slow. Thus, a comparison of k_{gly} , k_{age} , and/or K at two or more different time periods provides physiological condition information of the subject. For example, when a clinically significant change to k_{gly} , k_{age} , and/or K is observed over time an abnormal or diseased physiological condition may, and likely, exist.

[0139] For example, when k_{gly} significantly varies over time such that the variation is clinically significant, such clinically significant variation can indicate that the glucose transporter level or cell membrane has changed. Such biological changes may indicate a potential metabolic change in the subject's body resulting from the subject's physiology under-going a disease state.

[0140] When k_{age} and/or k_{gen} varies significantly over time such that the variation is clinically significant, such clinically significant variation can indicate changes to the subject's immune system because the immune system is designed to recognize cells that need to be removed.

[0141] A clinically significant variation in k_{age} and/or k_{gen} may also or alternatively be associated with the oxygen sensing mechanism in the body. An increasing k_{age} and/or k_{gen} over time may indicate that the subject's body needs the red blood cells to carry more oxygen or the oxygen sensing mechanism is not functioning correctly, either reason indicating a physiological state change such as for example, blood loss or a disease condition.

[0142] In yet another example (in combination or alternative of the foregoing examples), clinically significant variation in k_{age} and/or k_{gen} may be associated with bone marrow changes. For example, if the bone marrow suddenly produces a lot more oxygen carrying red blood cells, the subject's body will respond by killing off or eliminating more red blood cells. That is, a clinically significant increase in k_{age} and/or k_{gen} may be associated with bone marrow abnormality.

[0143] In another example, a hormone disorder can cause a clinically significant variation in k_{age} , k_{gen} , and K . Hormones can affect heart rate, contraction strength, blood volume, blood pressure, and red blood cell production. Stress hormones such as catecholamines and cortisol stimulate the release of reticulocytes from the bone marrow and possibly also enhance erythropoiesis. Therefore, large fluctuation on hormone level can change k_{age} and/or k_{gen} , and consequently K .

[0144] In yet another example, deviations from normal of the k_{gly} , k_{age} , and/or K may be an indicator of diabetes or pre-diabetes. Using k_{gly} , k_{age} , and/or K to measure diabetes or pre-diabetes may be more effective than standard fasting glucose tests and measured HbA1c. For instance, a subject with a measured HbA1c value in the normal range and normal fasting glucose may have low k_{gly} associated with high glucose values at times in the day other than fasting. Therefore, the subject may be a candidate for earlier diabetes intervention that otherwise may have gone unnoticed based on standard diabetes diagnosis methods.

[0145] In another example, for a subject with a newly high measured HbA1c, the standard diabetes treatments may be employed to lower their HbA1c.

However, determining that k_{gly} is abnormal may be an indication that the problem is with their glycation physiology rather than their pancreas, suggesting other more targeted forms of treatment.

[0146] Embodiments of the present disclosure include displaying the determined k_{gly} , k_{age} , and/or K , the changes in k_{gly} , k_{age} , and/or K over time, and/or possible abnormal or diseased physiological conditions.

[0147] In the manner described herein, in accordance with the embodiments of the present disclosure, the physiological parameter analysis provides an indication of a subject's abnormal or disease condition, as well as an analysis and/or monitoring tool for one or more parameters or characteristics for a subject's personalized diabetes management.

Identifying Supplements and/or Medicines

[0148] Several supplements and medications interact with the kinetics of red blood cell glycation, elimination, and generation within the body. For example, supplements and medicines used by athletes to dope include, but are not limited to, human growth hormones, supplements and medicines that increase metabolic levels, and the like. Human growth hormones can increase red blood cell count and, consequently, increase k_{age} . In another example, supplements and medicines that increase metabolic levels (e.g., exercise mimetics like AMPK agonists) can affect k_{gly} . Therefore, some embodiments may use one or more physiological parameters (k_{gly} , k_{age} , and/or K) as an indicator of doping.

[0149] In a first example, having one or more physiological parameters (k_{gly} , k_{age} , and/or K) outside normal ranges may be used, in some instances, as an indicator of doping.

[0150] In another example, once the one or more physiological parameters (k_{gly} , k_{age} , and/or K) are determined, continuous monitoring over a 10-day or longer period could identify sudden changes in the physiological parameters that could indicate doping. This could be used alone or in combination with the foregoing example of the one or more physiological parameters being outside normal ranges.

Physiological Age

[0151] The physiological parameters k_{age} and, consequently, K change due to aging. Therefore, k_{age} and/or K (provided a stable or known change in k_{gly}) may be used as biological markers to calculate a standardized metabolic age. Generally, over time, k_{age} decreases and K increases. Using a correlation between k_{age} and/or K and age in healthy subjects, a new subject's metabolic age may be calculated. This metabolic age may then be used as an indicator of the new subject's risk for age-related degenerative conditions like heart disease, Alzheimer's, or osteoporosis. The risk for age-related degenerative conditions may be used in conjunction with family history of age-related degenerative conditions for proactive screening and/or preventive treatment. For example, a 54-year old subject with a metabolic age of 65 with a family history of cardiovascular disease developing later in life may be tested more often for signs and/or progression of cardiovascular disease than a 54-year old subject with a metabolic age of 50 and a similar family history.

Grouping Decisions for Peer-Based Treatments

[0152] An individual's health condition may be treated using group program systems and methods that utilize peer interaction as a motivating force. In some examples, the health condition may include one or more of: pre-diabetes, heart disease, pre-hypertension, hypertension, pre-coronary atherosclerosis, pre-renal failure, combinations thereof, and others. The systems and methods can be used to facilitate the creation and/or maintenance of a social environment in which the participants interact with a facilitator and/or each other to more effectively follow a health regimen.

[0153] In many embodiments, methods of utilizing such group programs include a step of selecting a group of participants based on a common or similar characteristic amongst the participants. This selection can be performed using one or more of the physiological parameters described herein (e.g., k_{gly} , k_{age} (or k_{gen}), K , and/or $cHbA1c$) that match (e.g., have the same or similar values for the one or more physiological parameters). Participant groups can include any number of two or more participants (e.g., 8-16, 12-18, etc.).

[0154] One or more body metrics can be used to assess the extent to which a target or goal for the health regimen has been achieved. One or more of these physiological parameters (e.g., k_{gly} , k_{age} (or k_{gen}), K , and/or $cHbA1c$) can be used as the body metric, although such is not required. For example, the systems and methods can be used to guide participants diagnosed with prediabetes to lose weight to reduce their risk of developing diabetes, to guide participants diagnosed with obesity to lose weight through an exercise and/or diet regimen, and for other purposes. While reduction in body weight is a commonly used metric that can be measured to assess progress towards a goal, other body metrics can be used, including but not limited to: body mass index (BMI), body fat percentage, blood pressure, and cholesterol.

[0155] In addition to selection of the group, the methods can further include receiving a body metric measurement over a network from the participants of the matched group; determining a body metric measurement trend of each participant; and providing feedback to the participant based on the body metric measurement trend of the participant relative to the body metric measurement trend of the remainder of the matched group. This feedback can act as a motivator to stimulate further progress towards the target or goal. A facilitator leading the matched group and/or the participants in the matched group may provide feedback and support tailored to the matched group overall and/or to individual participants in the matched group. This process of receiving and analyzing measurements and providing feedback can be repeated periodically over the length of the program for continued motivation and progress.

[0156] Grouping a plurality of participants into a matched group functions to establish a community among participants. In addition to having at least one physiological parameter in common (e.g., k_{gly} , k_{age} (or k_{gen}), K , and/or $cHbA1c$), grouping decisions can be based on other factors, including but not limited to: a characteristic of a common goal (e.g., the goal of losing or gaining a certain percentage (e.g., 5%) of an individual respective starting weight, the goal of maintaining current starting weight or to attain a particular goal weight, the goal of losing, gaining, maintaining, or attaining a particular level or amount of BMI, body fat percentage, or other body metric measurement, the goal of reducing body fat

percentage, a common goal related to a health condition, such as preventing development of prediabetes to diabetes, and others); a common medical history (e.g., diagnosis of a particular condition at approximately the same time (e.g. diagnosed with pre-diabetes within two months of one another, or another suitable threshold), similar initial body weights, similar initial degree (class or stage) of congestive heart failure or other diagnosis of a cardiovascular disease, a similar degree of obesity, a similar stage of osteoarthritis or other joint disease that affects mobility, a similar diagnosis of depression or obsessive-compulsive disorder, or others); shared personality traits, or similar positions within a personality spectrum (e.g., similar results of a personality test or other assessment); a shared lifestyle characteristic or common interest (e.g., similar dietary restrictions or preferences (e.g., vegetarianism, veganism, nut-free, gluten-free), marriage status (e.g., married, divorced, widowed, single), children status (e.g., existence, age, gender, number of children), pet status (e.g., existence, age, species, number of pets), religious identification, similar hobbies or other interests (e.g., sports, television shows, cooking), or others); and/or similar personal information (e.g., gender, ethnicity or nationality, age, current geographical area, or occupational field, hometowns, schools attended, employers, or others). The making of grouping decisions based on having at least one physiological parameter in common (e.g., k_{gly} , k_{age} (or k_{gen}), K , and/or $cHbA1c$) and one or more of the aforementioned other factors can be a tiered or staged process that effectively places the various characteristics in a hierarchy of importance.

[0157] Further examples of group programs utilizing peer-based treatment, where a grouping decision can be based upon at least one of k_{gly} , k_{age} (or k_{gen}), K , and/or $cHbA1c$ are described in the following references that are incorporated by reference herein in their entireties for all purposes: U.S. Patent Publ. 2013/0117040 ("Method and System for Supporting a Health Regimen"); U.S. Patent Publ. 2014/0214442 ("Systems and Methods for Tracking Participants in a Health Improvement Program"); U.S. Patent Publ. 2014/0214443 ("Systems and Methods for Displaying Metrics Associated with a Health Improvement Program"); U.S. Patent Publ. 2014/0222454 ("Systems and Methods that Administer a Health Improvement

Program and an Adjunct Medical Treatment”); and U.S. Patent Publ. 2017/0344726 (“Method and System for Supporting a Health Regimen”).

Analyte Monitors and Monitoring Systems

[0158] Generally, embodiments of the present disclosure are used with or as systems, devices, and methods for measuring glucose and, in some instances, at least one other analyte in a bodily fluid. The embodiments described herein can be used to monitor and/or process information regarding glucose and, in some instances, at least one other analyte. Other analytes that may be monitored include, but are not limited to, glucose derivatives, HbA1c, acetylcholine, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glutamine, growth hormones, hormones, ketones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In embodiments that monitor glucose and one or more than one other analytes, each of the analytes may be monitored at the same or different times.

[0159] The analyte monitors and/or analyte monitoring systems (referred to herein collectively as analyte monitoring systems) used with or as systems, devices, and methods for measuring glucose and, in some instances, one or more analytes in a bodily fluid may be in vivo analyte monitoring systems or in vitro analyte monitoring systems. In some instances, systems, devices, and methods of the present disclosure may use both in vivo analyte monitoring systems and in vitro analyte monitoring systems.

[0160] In vivo analyte monitoring systems include analyte monitoring systems where at least a portion of an analyte sensor is, or can be, positioned in the body of a subject to obtain information about at least one analyte of the body. In vivo analyte monitoring systems can operate without the need for user calibration. Examples of in vivo analyte monitoring systems include, but are not limited to, continuous analyte monitoring systems and flash analyte monitoring systems.

[0161] Continuous analyte monitoring systems (e.g., continuous glucose monitoring systems), for example, are in vivo systems that can transmit data from a sensor control device to a reader device repeatedly or continuously without prompting (e.g., automatically according to a schedule).

[0162] Flash analyte monitoring systems (or flash glucose monitoring systems or simply flash systems), for example, are in vivo systems that can transfer data from a sensor control device in response to a scan or request for data by a reader device, such as with a near field communication (NFC) or radio frequency identification (RFID) protocol.

[0163] In vivo analyte monitoring systems can include a sensor that, while positioned in vivo, makes contact with the bodily fluid of the subject and senses one or more analyte levels contained therein. The sensor can be part of a sensor control device that resides on the body of the subject and contains the electronics and power supply that enable and control the analyte sensing. The sensor control device, and variations thereof, can also be referred to as a "sensor control unit," an "on-body electronics" device or unit, an "on-body" device or unit, or a "sensor data communication" device or unit, to name a few. As used herein, these terms are not limited to devices with analyte sensors, and encompass devices that have sensors of other types, whether biometric or non-biometric. The term "on body" refers to any device that resides directly on the body or in close proximity to the body, such as a wearable device (e.g., glasses, watch, wristband or bracelet, neckband or necklace, etc.).

[0164] In vivo analyte monitoring systems can also include one or more reader devices that receive sensed analyte data from the sensor control device. These reader devices can process and/or display the sensed analyte data, in any number of forms, to the subject. These devices, and variations thereof, can be referred to as "handheld reader devices," "reader devices" (or simply, "readers"), "handheld electronics" (or handhelds), "portable data processing" devices or units, "data receivers," "receiver" devices or units (or simply receivers), "relay" devices or units, or "remote" devices or units, to name a few. Other devices such as personal computers have also been utilized with or incorporated into in vivo and in vitro monitoring systems.

[0165] For example, referring to FIG. 3, a sensor or portion thereof of an in vivo analyte monitoring system may be the glucose monitor 324, and the reader device may be the health monitoring device 320. In alternative embodiments, the in vivo analyte monitoring system may be, in whole, the glucose monitor 324 that transmits data to a health monitoring device 320, data network 322, data processing terminal/PC 326, and/or server/cloud 328.

[0166] For in vivo analyte monitoring systems, the determination of one or more physiological parameters (e.g., k_{gly} , k_{age} (or k_{gen}), and/or K) and/or other analyses described herein may be performed within the in vivo analyte monitoring system, in some instances. Only the physiological parameters may, for example, be determined within the in vivo analyte monitoring system and transmitted to a suitable other component of a physiological parameter analysis system, which may perform other analyses described herein. In some embodiments, the in vivo analyte monitoring system may only produce output signals that correspond to glucose levels that are received by another component of a physiological parameter analysis system. In such cases, one or more of the other component(s) of the physiological parameter analysis system may determine one or more physiological parameters (e.g., k_{gly} , k_{age} (or k_{gen}), and/or K) and, in some instances, perform one or more of the other analyses described herein.

[0167] FIG. 8 illustrates an example of an in vivo analyte monitoring system 860. For embodiments of the present disclosure this example in vivo analyte monitoring system 860 monitors glucose and, in some instances, one or more other analytes. Other analytes of interest with respect to human physiology may include, for example, lactate, oxygen, pH, A1c, ketones, drug levels, and the like. Any of these analytes may exhibit temperature-insensitive permeability through the polymeric membrane compositions disclosed herein. Both single analytes and any combination of the foregoing analytes may be assayed.

[0168] The in vivo analyte monitoring system 860 comprises a sensor control device 862 (which may be at least a portion of the glucose monitor 324 of FIG. 3) and a reader device 864 (which may be at least a portion of the health monitoring device 320 of FIG. 3) that communicate with each other over a local communication path (or link) 866, which can be wired or wireless, uni-directional or

bi-directional, and/or encrypted or non-encrypted. Any suitable electronic communication protocol may be used for each of the local communication paths 866 or links. For example, in embodiments where path 866 is wireless, a near field communication (NFC) protocol, RFID protocol, BLUETOOTH® or BLUETOOTH® Low Energy protocol, WiFi protocol, proprietary protocol, or the like can be used, including those communication protocols in existence as of the date of this filing or their later developed variants.

[0169] Reader device 864 (e.g., a dedicated reader, a cellular phone or PDA running an app, or the like) is also capable of wired, wireless, or combined communication with a computer system 868 (which may be at least a portion of the data processing terminal/PC 326 of FIG. 3) over communication path (or link) 870 and with a network 872 (which may be at least a portion of the data network 322 and/or the server/cloud 328 of FIG. 3), such as the internet or the cloud, over communication path (or link) 874. Communication with network 872 can involve communication with trusted computer system 876 within network 872, or through network 872 to computer system 868 via communication link (or path) 878. Communication paths 870, 874, and 878 can be wireless, wired, or both, can be uni-directional or bi-directional, can be encrypted or non-encrypted, and can be part of a telecommunications network, such as a Wi-Fi network, a local area network (LAN), a wide area network (WAN), the internet, or other data network. In some cases, communication paths 870 and 874 can be the same path. All communications over paths 866, 870, and 874 can be encrypted and sensor control device 862, reader device 864, computer system 868, and trusted computer system 876 can each be configured to encrypt and decrypt those communications sent and received.

[0170] Variants of devices 862 and 864, as well as other components of an in vivo-based analyte monitoring system that are suitable for use with the system, device, and method embodiments set forth herein, are described in U.S. Patent Application Publication No. 2011/0213225 (hereinafter the '225 Publication), which is incorporated by reference herein in its entirety for all purposes.

[0171] Sensor control device 862 can include a housing 880 containing in vivo analyte monitoring circuitry and a power source. In this embodiment, the in vivo analyte monitoring circuitry is electrically coupled with an analyte sensor 882 that

extends through an adhesive patch 884 and projects away from housing 880. Adhesive patch 884 contains an adhesive layer (not shown) for attachment to a skin surface of the body of the subject. Other forms of body attachment to the body may be used, in addition to or instead of adhesive. Suitable adhesives for inclusion in the adhesive layer will be familiar to one having ordinary skill in the art.

[0172] Sensor 882 is adapted to be at least partially inserted into a tissue of interest, such as the dermal layer or subcutaneous layer of the skin. Sensor 882 may comprise a sensor tail of sufficient length for insertion to a desired depth in a given tissue. The sensor tail may comprise a sensing region that is active for sensing, and may comprise an enzyme, a polymeric membrane, and other components. One or more analyte levels may be determined using sensor 882 and undergo communication to reader device 864. The analyte may be monitored in any biological fluid such as dermal fluid, plasma, blood, lymph, or the like.

[0173] Sensor 882 and any accompanying sensor control electronics can be applied to the body in any desired manner. For example, an introducer may be present transiently to promote introduction of sensor 882 into a tissue. In illustrative embodiments, the introducer may comprise a needle. It is to be recognized that other types of introducers, such as sheaths or blades, may be present in alternative embodiments. More specifically, the needle or similar introducer may transiently reside in proximity to sensor 882 prior to insertion and then be withdrawn afterward. While present, the needle or other introducer may facilitate insertion of sensor 882 into a tissue by opening an access pathway for sensor 882 to follow. For example, the needle may facilitate penetration of the epidermis as an access pathway to the dermis to allow implantation of sensor 882 to take place, according to one or more embodiments. After opening the access pathway, the needle or other introducer may be withdrawn so that it does not represent a sharps hazard. In illustrative embodiments, the needle may be solid or hollow, beveled or non-beveled, and/or circular or non-circular in cross-section. In more particular embodiments, the needle may be comparable in cross-sectional diameter and/or tip design to an acupuncture needle, which may have a cross-sectional diameter of about 250 microns. It is to be recognized, however, that suitable needles may have a larger or smaller cross-sectional diameter if needed for particular applications. In alternative embodiments,

the needle or similar introducers may be absent, provided sensor 882 is sufficiently robust to penetrate a tissue and establish communication with a bodily fluid of interest.

[0174] In some embodiments, a tip of the needle may be angled over the terminus of sensor 882, such that the needle penetrates a tissue first and opens an access pathway for sensor 882. In other illustrative embodiments, sensor 882 may reside within a lumen or groove of the needle, with the needle similarly opening an access pathway for sensor 882. In either case, the needle is subsequently withdrawn after facilitating insertion.

[0175] Examples of introducers (also known as insertion devices) are described in U.S. Patent Application Publication Nos. 2008/0009692, 2011/0319729, 2015/0018639, 2015/0025345, and 2015/0173661, all which are incorporated by reference herein in their entireties and for all purposes.

[0176] It is to be recognized that analyte monitoring system 860 may comprise additional features and functionality that are not necessarily described herein in the interest of brevity. Accordingly, the foregoing description of analyte monitoring system 860 should be considered illustrative and non-limiting in nature.

[0177] After collecting raw data from the subject's body, sensor control device 862 can apply analog signal conditioning to the data and convert the data into a digital form of the conditioned raw data. In some embodiments, this conditioned raw digital data can be encoded for transmission to another device (e.g., reader device 864), which then algorithmically processes that digital raw data into a final form representative of the subject's measured biometric (e.g., a form readily made suitable for display to the subject or readily used in the analysis module 320B of FIG. 3). This algorithmically processed data can then be formatted or graphically processed for digital display to the subject. In other embodiments, sensor control device 862 can algorithmically process the digital raw data into the final form that is representative of the subject's measured biometric (e.g., analyte level) and then encode and wirelessly communicate that data to reader device 864, which in turn can format or graphically process the received data for digital display to the subject. In other embodiments, sensor control device 862 can graphically process the final form of the data such that it is ready for display, and display that data on a display of

sensor control device 862 or transmit the data to reader device 864. In some embodiments, the final form of the biometric data (prior to graphic processing) is used by the system (e.g., incorporated into a diabetes monitoring regime) without processing for display to the subject. In some embodiments, sensor control device 862 and reader device 864 transmit the digital raw data to another computer system for algorithmic processing and display.

[0178] Reader device 864 can include a display 886 to output information to the subject (e.g., one or more physiological parameter or an output derived therefrom like cHbA1c) and/or to accept an input from the subject and/or healthcare provider (e.g., a measured RPI value and/or a measured HbA1c value) and an optional input component 888 (or more) (e.g., a button, actuator, touch sensitive switch, capacitive switch, pressure sensitive switch, jog wheel or the like) to input data, commands, or otherwise control the operation of reader device 864. In certain embodiments, display 886 and input component 888 may be integrated into a single component, for example, where the display can measure the presence and location of a physical contact touch upon the display, such as a touch screen subject interface (which may be at least a portion of the subject interface 320A of FIG. 3). In certain embodiments, input component 888 of reader device 864 may include a microphone and reader device 864 may include software configured to analyze audio input received from the microphone, such that functions and operation of the reader device 864 may be controlled by voice commands. In certain embodiments, an output component of reader device 864 includes a speaker (not shown) for outputting information as audible signals. Similar voice responsive components such as a speaker, microphone and software routines to generate, process, and store voice driven signals may be included in sensor control device 862.

[0179] Reader device 864 can also include one or more data communication ports 890 for wired data communication with external devices such as computer system 868. Example data communication ports 890 include, but are not limited to, USB ports, mini USB ports, USB Type-C ports, USB micro-A and/or micro-B ports, RS-232 ports, Ethernet ports, Firewire ports, or other similar data communication ports configured to connect to the compatible data cables. Reader device 864 may also include an integrated or attachable in vitro glucose meter, including an in vitro

test strip port (not shown) to receive an in vitro glucose test strip for performing in vitro blood glucose measurements.

[0180] Reader device 864 can display the measured biometric data wirelessly received from sensor control device 862 and can also be configured to output alarms (e.g., a visual alarm on a display, an auditory alarm, or a combination thereof), alert notifications, glucose levels, etc., which may be visual, audible, tactile, or any combination thereof. Further details and other display embodiments can be found in U.S. Patent Application Publication No. 2011/0193704, for example, which is incorporated herein by reference in its entirety for all purposes.

[0181] Reader device 864 can function as a data conduit to transfer the measured data from sensor control device 862 to computer system 868 or trusted computer system 876. In certain embodiments, the data received from sensor control device 862 may be stored (permanently or temporarily) in one or more memories of reader device 864 prior to uploading to computer system 868, trusted computer system 876, or network 872.

[0182] Computer system 868 may be a personal computer, a server terminal, a laptop computer, a tablet, or other suitable data processing device. Computer system 868 can be (or include) software for data management and analysis and communication with the components in analyte monitoring system 860. Computer system 868 can be used by the subject, a medical professional, or other user to display and/or analyze the biometric data measured by sensor control device 862. In some embodiments, sensor control device 862 can communicate the biometric data directly to computer system 868 without an intermediary such as reader device 864, or indirectly using an internet connection (also, in some instances, without first sending to reader device 864). Operation and use of computer system 868 is further described in the '225 Publication incorporated herein. Analyte monitoring system 860 can also be configured to operate with a data processing module (not shown), also as described in the incorporated '225 Publication.

[0183] Trusted computer system 876 can be within the possession of the manufacturer or distributor of sensor control device 862, either physically or virtually through a secured connection, and can be used to perform authentication of sensor control device 862, for secure storage of the subject's biometric data, and/or as a

server that hosts a data analytics program (e.g., accessible via a web browser) for performing analysis on the subject's measured data.

[0184] In vivo analyte monitoring systems can be used in conjunction with or as a portion of an integrated diabetes management system. For example, an integrated diabetes management system may include an in vivo analyte monitoring system and a supplement/medication delivery system, and more specifically, an in vivo glucose monitoring system and an insulin delivery system (e.g., an insulin pump). Integrated diabetes management systems may be closed-loop, open-loop, or a hybrid thereof. Closed-loop systems are in full control of analyte measurement times and supplement/medication dosages and times. Open-loop systems allow a subject to be in full control of analyte measurement times and supplement/medication dosages and times. Hybrid systems can rely primarily on a closed-loop system methodology but allow a subject to intervene.

[0185] In vitro analyte monitoring systems contact a bodily fluid outside of the body. In some instances, in vitro analyte monitoring systems include a meter device that has a port for receiving the bodily fluid of the subject (e.g., on an analyte test strip/swab or via collection of the bodily fluid), which can be analyzed to determine the subject's analyte level.

Example Embodiments

[0186] Examples of embodiments of the present disclosure include Embodiment A, Embodiment B, Embodiment C, Embodiment D, Embodiment E, Embodiment F, Embodiment G, Embodiment H, Embodiment I, and Embodiment J. Combinations of such embodiments are also included as part of the present disclosure.

[0187] Embodiment A is a method comprising: providing (or receiving) a plurality of glucose levels over a first time period; providing (or receiving) a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; providing (or receiving) a reticulocyte production index (RPI) value corresponding to a time during the first time period; determining (e.g., calculating) a red blood cell elimination constant (k_{age}) from the RPI value; and determining (e.g., calculating) at least one physiological parameter selected from the group consisting of: a red blood

cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of glucose levels, (2) the first HbA1c level, and (3) the k_{age} .

[0188] Embodiment B is a method comprising: measuring a plurality of glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring a reticulocyte production index (RPI) value corresponding to a time during the first time period; determining (e.g., calculating) a red blood cell elimination constant (k_{age}) from the RPI value; and determining (e.g., calculating) at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of glucose levels, (2) the first HbA1c level, and (3) the k_{age} .

[0189] Embodiment A or B may include additional elements, which may include, but are not limited to: Element 1: wherein the first time period is about 300 days or longer and the plurality of glucose levels occur on average about 96 or more times daily; Element 2: the method further comprising measuring a second HbA1c level corresponding to a beginning of the first time period and, in some instances, wherein the first time period is about 30 days or longer, and the plurality of glucose levels occur on average about 24 or more times daily; Element 3: wherein at least some of the plurality of glucose levels are measured with an in vivo analyte sensor having a portion positioned to be in contact with a bodily fluid, the in vivo analyte sensor generating signals corresponding to a plurality of glucose levels in the bodily fluid; Element 4: Element 3 and wherein the bodily fluid comprises a fluid selected from the group consisting of: blood, dermal fluid, interstitial fluid, or a combination thereof; Element 5: Element 3 and wherein the in vivo analyte sensor is a component of a closed-loop control system or a hybrid closed-loop control system for delivering an insulin dosage; Element 6: wherein at least some of the plurality of glucose levels are measured by a continuous glucose monitoring system; Element 7: wherein at least some of the plurality of glucose levels are input based on an in vitro glucose level measurement; Element 8: Element 7 and wherein the in vitro glucose level measurement measures the plurality of glucose levels in a fluid selected from the

group consisting of: blood, interstitial fluid, subcutaneous fluid, dermal fluid, sweat, tears, saliva, or a combination thereof; Element 9: the method further comprising displaying the at least one physiological parameter; Element 10: the method further comprising calculating an error associated with the at least one physiological parameter; and measuring at least one new glucose level and/or measuring at least one new HbA1c level when the error is at or greater than about 7%; Element 11: the method further comprising calculating a metabolic age based on k_{age} and/or K ; Element 12: the method further comprising calculating a personalized-target glucose range based on the at least one physiological parameter; Element 13: the method further comprising calculating a personalized-target average glucose based on the at least one physiological parameter; Element 14: the method further comprising calculating a cHbA1c based on the at least one physiological parameter and a plurality of glucose levels over a second time period following the first time period and, in some instances, wherein the plurality of glucose levels over the second time period are at a plurality of times separated by a time interval t_i that is (a) greater than or equal to three hours and less than or equal to twenty-four hours and/or (b) at least twice a maximum gap duration between temporally adjacent glucose levels in the plurality of glucose levels over the second time period; Element 15: the method further comprising triaging a subject's treatment based on the at least one physiological parameter; Element 16: the method further comprising adjusting a dosage of diabetes medication based on the at least one physiological parameter; Element 17: the method further comprising adjusting a dosage of glycation medication based on the at least one physiological parameter; Element 18: the method further comprising determining an abnormal or diseased physiological condition of a subject based on the at least one physiological parameter; and Element 19: the method further comprising determining a type of a medication or supplement in a subject's body based on the at least one physiological parameter. Examples of combinations of elements include, but are not limited to, two or more of Elements 11-19 in combination; Elements 6 and 7 in combination, optionally in further combination with Element 8; Element 6 in combination with Element 3, optionally in further combination with one or both of Elements 4-5; Elements 9-10 in combination; Element 9 and/or Element 10 in combination with one or more of Elements 11-19;

one or more of Elements 3-8 in combination with one or more of Elements 11-19; and Element 1 or Element 2 in combination with one or more of Elements 3-19 including any of the foregoing combinations of Elements 3-19.

[0190] Embodiment C is an apparatus comprising: one or more processors; and a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: receive a plurality of glucose levels over a first time period; receive a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; receive a reticulocyte production index (RPI) value corresponding to a time during the first time period; determine a red blood cell elimination constant (k_{age}) from the RPI value; and determine at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of glucose levels, (2) the first HbA1c level, and (3) the k_{age} . Alternatively, the k_{age} calculated based on the RPI can be received instead of the RPI.

[0191] Embodiment D is a system comprising: an analyte sensor configured to measure a glucose level in a bodily fluid; and a monitoring device comprising: one or more processors; and a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: receive a plurality of glucose levels over a first time period from the analyte sensor; receive a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; receive a reticulocyte production index (RPI) value corresponding to a time during the first time period; determine a red blood cell elimination constant (k_{age}) from the RPI value; and determine at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of glucose levels, (2) the first HbA1c level, and (3) the k_{age} . Alternatively, the k_{age} calculated based on the RPI can be received instead of the RPI.

[0192] Embodiment E is a system comprising: one or more processors; an in vivo analyte sensor having a portion positioned to be in contact with a bodily fluid,

the in vivo analyte sensor generating signals corresponding to glucose levels in the bodily fluid; a transmitter coupled to the in vivo analyte sensor and to at least one processor of the one or more processors; and a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: receive a plurality of glucose levels over a first time period from the analyte sensor; receive a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; receive a reticulocyte production index (RPI) value corresponding to a time during the first time period; determine a red blood cell elimination constant (k_{age}) from the RPI value; and determine at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K), based on (1) the plurality of glucose levels, (2) the first HbA1c level, and (3) the k_{age} . Alternatively, the k_{age} calculated based on the RPI can be received instead of the RPI.

[0193] Embodiments C, D, and E may include additional elements, which may include, but are not limited to: Element 1; Element 20: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: receive a second HbA1c level corresponding to a beginning of the first time period and, in some instances, wherein the first time period is about 30 days or longer and the plurality of glucose levels occur on average about 24 or more times daily; Element 21: configured to receive at least some of the plurality of glucose levels from an in vivo analyte sensor having a portion positioned to be in contact with bodily fluid; Element 22: configured to receive at least some of the plurality of glucose levels from a continuous glucose monitoring system; Element 23: configured to receive at least some of the plurality of glucose levels from a subject based on an in vitro glucose level measurement; Element 24: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: display the at least one physiological parameter; Element 25: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: determine an error associated with the at least one physiological parameter; and request at least one new glucose level and/or request at least one new HbA1c level when the error is at or greater than about 7%; Element

26: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: calculate a metabolic age based on k_{age} and/or K and, in some instances, output a report that includes the metabolic age; Element 27: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: calculate a personalized-target glucose range based on the at least one physiological parameter and, in some instances, output a report that includes the personalized-target glucose range; Element 28: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: calculate a personalized-target average glucose based on the at least one physiological parameter and, in some instances, output a report that includes the personalized-target average glucose; Element 29: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: calculate a $CHbA1c$ based on the at least one physiological parameter and a plurality of glucose levels over a second time period following the first time period and, in some instances, output a report that includes the $CHbA1c$, and, in some instances, wherein the plurality of glucose levels over the second time period are at a plurality of times separated by a time interval t_i that is (a) greater than or equal to three hours and less than or equal to twenty-four hours, (b) at least twice a maximum gap duration between temporally adjacent glucose levels in the plurality of glucose levels over the second time period, or (c) both (a) and (b); Element 30: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: output a triage recommendation for a subject's treatment based on the at least one physiological parameter and, in some instances, output a report that includes the triage recommendation; Element 31: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: output a dosage of diabetes medication based on the at least one physiological parameter and, in some instances, output a report that includes the dosage of diabetes medication; Element 32: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: output a dosage of glycation medication based on the at least one physiological parameter and, in some instances, output a report that includes the

dosage of glycation medication; Element 33: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: output an abnormal or diseased physiological condition of a subject based on the at least one physiological parameter and, in some instances, output a report that includes the abnormal or diseased physiological condition; and Element 34: wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: output a type of a medication or supplement in a subject's body based on the at least one physiological parameter and, in some instances, output a report that includes the type of the medication or supplement. Examples of combinations of elements include, but are not limited to, two or more of Elements 26-34 in combination; two or more of Elements 21-25 in combination; one or more of Elements 21-25 in combination with one or more of Elements 26-34; Element 1 or Element 20 in combination with one or more of Elements 21-34 including any of the foregoing combinations of Elements 21-34.

[0194] Embodiment F is a system comprising: an analyte sensor configured to measure a glucose level in a bodily fluid; and a monitoring device comprising: one or more processors; and a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: determine, based on (1) a plurality of first glucose levels taken over a first time period and (2) a first HbA1c level, at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), a red blood cell elimination constant (k_{age}), and an apparent glycation constant (K); determine a calculated glycated hemoglobin (cHbA1c) level based on the at least one physiological parameter and a plurality of second glucose levels at a plurality of times separated by a time interval t_i , wherein the time interval t_i is (a) greater than or equal to three hours and less than or equal to twenty-four hours, (b) at least twice a maximum gap between temporally adjacent glucose levels present in the plurality of second glucose levels, or (c) both (a) and (b), wherein the plurality of second glucose levels is for a second time period after the first time period; and output the cHbA1c level.

[0195] Embodiment G is a computer implemented method for determining a glycated hemoglobin level comprising: determining, based on (1) a plurality of first glucose levels taken over a first time period and (2) a first HbA1c level corresponding to an end of the first time period, at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), a red blood cell elimination constant (k_{age}), and an apparent glycation constant (K); determining a calculated glycated hemoglobin (cHbA1c) level based on the at least one physiological parameter and a plurality of second glucose levels at a plurality of times separated by a time interval t_i , wherein the time interval t_i is (a) greater than or equal to three hours and less than or equal to twenty-four hours, (b) at least twice a maximum gap between temporally adjacent glucose levels present in the plurality of second glucose levels, or (c) both (a) and (b) wherein the plurality of second glucose levels is for a second time period after the first time period; and outputting the cHbA1c level.

[0196] Embodiments F or G may include additional elements, which may include, but are not limited to: Element 1, Element 2, Element 3 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), Element 4, Element 5, Element 6 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), Element 7 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), one or more of Elements 8-14, and one or more of Elements 16-19. Examples of combinations of elements include, but are not limited to, two or more of Elements 11-19 in combination; Elements 6 and 7 in combination, optionally in further combination with Element 8; Element 6 in combination with Element 3, optionally in further combination with one or both of Elements 4-5; Elements 9-10 in combination; Element 9 and/or Element 10 in combination with one or more of Elements 11-14 and 16-19; one or more of Elements 3-8 in combination with one or more of Elements 11-14 and 16-19; and Element 1 or Element 2 in combination with one or more of Elements 3-14 and 16-19 including any of the foregoing combinations of Elements 3-14 and 16-19.

[0197] Embodiment H is a system for determining a matched group of participants in a peer-based treatment program comprising: an analyte sensor

configured to measure a glucose level in a bodily fluid; and a monitoring device comprising: one or more processors; and a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to: determine, based on (1) a plurality of first glucose levels taken over a first time period and (2) a first HbA1c level, at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), a red blood cell elimination constant (k_{age}), and an apparent glycation constant (K); determine a matched group of participants in a peer-based treatment program using the at least one physiological parameter; and output the matched group of participants.

[0198] Embodiment I is a computer implemented method for determining a matched group of participants in a peer-based treatment program comprising: determining, based on (1) a plurality of first glucose levels taken over a first time period and (2) a first HbA1c level corresponding to an end of the first time period, at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), a red blood cell elimination constant (k_{age}), and an apparent glycation constant (K); determining a matched group of participants in a peer-based treatment program using the at least one physiological parameter; and outputting the matched group of participants.

[0199] Embodiments H or I may include additional elements, which may include, but are not limited to: Element 1, Element 2, Element 3 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), Element 4, Element 5, Element 6 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), Element 7 (as applied to either or both of the plurality of first glucose levels and the plurality of second glucose levels), and one or more of Elements 8-19. Examples of combinations of elements include, but are not limited to, two or more of Elements 11-19 in combination; Elements 6 and 7 in combination, optionally in further combination with Element 8; Element 6 in combination with Element 3, optionally in further combination with one or both of Elements 4-5; Elements 9-10 in combination;

Element 9 and/or Element 10 in combination with one or more of Elements 11-19; one or more of Elements 3-8 in combination with one or more of Elements 11-19; and Element 1 or Element 2 in combination with one or more of Elements 3-19 including any of the foregoing combinations of Elements 3-19.

[0200] Unless otherwise indicated, all numbers expressing quantities and the like in the present specification and associated claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the embodiments of the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claim, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0201] One or more illustrative embodiments incorporating various features are presented herein. Not all features of a physical implementation are described or shown in this application for the sake of clarity. It is understood that in the development of a physical embodiment incorporating the embodiments of the present disclosure, numerous implementation-specific decisions must be made to achieve the developer's goals, such as compliance with system-related, business-related, government-related and other constraints, which vary by implementation and from time to time. While a developer's efforts might be time-consuming, such efforts would be, nevertheless, a routine undertaking for those of ordinary skill in the art and having benefit of this disclosure.

[0202] While various systems, tools and methods are described herein in terms of "comprising" various components or steps, the systems, tools and methods can also "consist essentially of" or "consist of" the various components and steps.

[0203] As used herein, the phrase "at least one of" preceding a series of items, with the terms "and" or "or" to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase "at least one of" allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items.

By way of example, the phrases "at least one of A, B, and C" or "at least one of A, B, or C" each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.

[0204] To facilitate a better understanding of the embodiments of the present invention, the following examples of preferred or representative embodiments are given. In no way should the following examples be read to limit, or to define, the scope of the invention.

EXAMPLES

[0205] Data from 148 type 2 and 139 type 1 subjects enrolled in two previous clinical studies having six months of continuous glucose monitoring were analyzed. Only 90 subjects had sufficient data to meet the kinetic model assumptions described above having data with no continuous glucose data gap 12 hours or longer. Study participants had three HbA1c measurements, on days 1, 100 (± 5 days), and 200 (± 5 days), as well as frequent subcutaneous glucose monitoring throughout the analysis time period, which allowed for analysis of two independent data sections (days 1-100 and days 101-200) per participant.

[0206] The first data section (days 1-100) was used to numerically estimate individual k_{gly} and k_{age} , which allows prospective calculation of ending cHbA1c of the second data section (days 101-200). This ending cHbA1c can be compared with the observed ending HbA1c to validate the kinetic model described herein. For comparison, an estimated HbA1c for the second data section was calculated based on (1) 14-day mean and (2) 14-day weighted average glucose converted by the accepted regression model from the A1c-Derived Average Glucose (ADAG) study, which both assume k_{gly} is a constant, which as discussed previously is the currently accepted method of relating HbA1c to glucose measurements.

[0207] FIGS. 9A-C illustrate a comparison between the laboratory HbA1c levels at day 200 (± 5 days) relative to the estimated HbA1c values, where the eHbA1c values in the 9A plot are calculated using the 14-day mean model, the eHbA1c values in the 9B plot are calculated using the 14-day weighted average model, and the cHbA1c values in the 9C plot are calculated using the kinetic model described herein (Equation 8). The solid line in all graphs illustrates the linear

regression of the comparative HbA1c values for the corresponding models. The dashed line is a one-to-one line, where the closer the solid line linear regression is thereto, the better the model. Clearly, the kinetic model described herein models the data better, which illustrates that k_{age} and k_{gly} are individualized, which is a novel way to approach correlating HbA1c to glucose measurements.

[0208] FIG. 10 illustrates an example study subject's data with the measured glucose levels (solid line), laboratory HbA1c readings (open circles), cHbA1c model values (long dashed line), and 14-day eHbA1c model values (dotted line). The cHbA1c model values in FIG. 10 were calculated using the physiological parameters (k_{age} and k_{gly}). The physiological parameters were calculated based on the first two laboratory HbA1c readings and glucose levels measured between the first two laboratory HbA1c readings. The 14-day eHbA1c values are glucose level 14-day running averages during the study.

[0209] The FIG. 10 example shows the dynamic nature of the glucose-to-cHbA1c and glucose-to-eHbA1c relationships. Additional examples were determined for type 1 and type 2 diabetes study participants across a range of prediction deviations: 25th, 50th and 75th percentiles for the cHbA1c method. In these examples, the disagreement between the cHbA1c from the 14-day average glucose indicates the exaggerated amplitude of variation inherent in the simple 14-day method.

[0210] FIG. 11 illustrates the relationship between steady glucose and equilibrium HbA1c (1) as determined using the standard conversion of HbA1c to estimated average glucose (dashed line with error bars) and (2) as measured for the 90 participants (solid lines). These individual curves (solid lines) represent the agreement of average glucose with laboratory measure HbA1c under the condition of their average glucose level being stable for days-to-weeks. The model suggests that the relationship of glucose-to-HbA1c is not constant, with larger changes in glucose needed to achieve the same change in HbA1c as levels of the latter marker increase. Contrary to prior assessments of the glycation index, the kinetic model of the present disclosure suggests that an individual's glycation index will not be constant across all levels of HbA1c. Unlike eHbA1c, a key advantage of cHbA1c is its ability to account for individual variation in glycation. Individuals with lower K are "low glycaters", and

have higher average glucose levels for a given HbA1c level, with the reverse being true for those with high K values.

[0211] Using the kinetic model of the present disclosure, a relationship between K (dL/mg) and mean glucose level target (mg/dL) is illustrated in FIG. 12 plotted for varying HbA1c target values. That is, if a subject is targeting a specific HbA1c value (e.g., for a subsequent HbA1c measurement or cHbA1c estimation) and has a known K value (e.g., based on a plurality of measured glucose levels and at least one measured HbA1c), a mean glucose target can be derived and/or identified for the subject over the time period in which the subject is targeting the HbA1c value.

[0212] Therefore, the disclosed systems, tools and methods are well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the teachings of the present disclosure may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered, combined, or modified and all such variations are considered within the scope of the present disclosure. The systems, tools and methods illustratively disclosed herein may suitably be practiced in the absence of any element that is not specifically disclosed herein and/or any optional element disclosed herein. While systems, tools and methods are described in terms of "comprising," "containing," or "including" various components or steps, the systems, tools and methods can also "consist essentially of" or "consist of" the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. In particular, every range of values (of the form, "from about a to about b," or, equivalently, "from approximately a to b," or, equivalently, "from approximately a-b") disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite

articles "a" or "an," as used in the claims, are defined herein to mean one or more than one of the elements that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted.

CLAIMS

What is claimed is the following:

1. A method comprising:

measuring a plurality of first glucose levels in a bodily fluid over a first time period;

measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period;

measuring a reticulocyte production index (RPI) value;

calculating a red blood cell elimination constant (k_{age}) based on the RPI value, wherein

$$k_{age} = RPI * (3.47 \text{ day}^{-1}) * (1 - \ln 2);$$

calculating, using (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the k_{age} , at least one first physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K); and

adjusting a glucose level target based on the at least one first physiological parameter.

2. The method of claim 1, wherein the glucose level target is one or more value selected from the group consisting of a personalized lower glucose limit, a personalized upper glucose limit, and a personalized-target glucose average.

3. The method of claim 2, wherein the at least one first physiological parameter comprises K, and the personalized upper glucose limit equals $0.087/K$.

4. The method of claim 2, wherein the at least one first physiological parameter comprises k_{giy} , and wherein the personalized lower glucose limit equals $3.35 \times 10^{-4} / k_{giy}$.
5. The method of claim 2, wherein the at least one first physiological parameter comprises K , and wherein the personalized-target average glucose (GT) equals $AT / (K(1-AT))$ where AT is a target HbA1c level.
6. The method of claim 1 further comprising:
 - measuring a second HbA1c corresponding to a beginning of the first time period, wherein determination of the at least one first physiological parameter is further based on (4) the second HbA1c.
7. The method of claim 1 further comprising:
 - calculating an error associated with the at least one first physiological parameter; and
 - receiving at least one new glucose level and/or receiving at least one new HbA1c level when the error is at or greater than about 7%.
8. The method of claim 1 further comprising :
 - treating a subject based on the glucose level target.
9. The method of claim 8, wherein treating the subject comprises administering and/or adjusting: an insulin dosage, a glycation-medication dosage, an exercise regime, a meal intake, or a combination thereof.
10. The method of claim 1, wherein the bodily fluid is selected from the group consisting of: blood, dermal fluid, interstitial fluid, or a combination thereof.

11. The method of claim 1 further comprising:
displaying the glucose level target.
12. The method of claim 1 further comprising:
receiving a glucose level of a subject after adjusting the glucose level target; and
displaying an alarm when the glucose level is outside the glucose level target.
13. The method of claim 1 further comprising:
calculating a metabolic age based on k_{age} and/or K .
14. The method of claim 1 further comprising:
receiving a plurality of second glucose levels for a second time period after the first time period; and
determining a calculated glycated hemoglobin (cHbA1c) level based on (1) the k_{giy} , (2) the k_{age} , (3) the plurality of second glucose levels for the second time period, and (4) the first HbA1c level.
15. The method of claim 1 further comprising:
receiving a second HbA1c level for an end of a second time period following the first time period;
calculating at least one second physiological parameter corresponding to the at least one first physiological parameter; and
identifying (1) a presence of an abnormal or diseased physiological condition and/or (2) an indicator of doping based on a comparison of the at least one first physiological parameter and the at least one second physiological parameter.

16. A system comprising:

an analyte sensor configured to measure a glucose level in a bodily fluid; and

a monitoring device comprising:

one or more processors; and

a memory operatively coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, causes the one or more processors to:

receive a plurality of first glucose levels in the bodily fluid over a first time period from the analyte sensor;

receive a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period;

receive a reticulocyte production index (RPI) value;

determine a red blood cell elimination constant (k_{age}) based on the RPI value, wherein

$$k_{age} = RPI * (3.47 \text{ day}^{-1}) * (1 - \ln 2);$$

determine, based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) k_{age} at least one first physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k_{gly}), a red blood cell generation rate constant (k_{gen}), and an apparent glycation constant (K); and

adjust a glucose level target based on the at least one first physiological parameter.

17. The system of claim 16, wherein the glucose level target is one or more value selected from the group consisting of a personalized lower glucose limit, a personalized upper glucose limit, and a personalized-target glucose average.

18. The system of claim 17, wherein the at least one first physiological parameter comprises K , and the personalized upper glucose limit equals $0.087/K$.

19. The system of claim 17, wherein the at least one first physiological parameter comprises k_{giy} , and wherein the personalized lower glucose limit equals $3.35 \times 10^{-4}/k_{giy}$.

20. The system of claim 17, wherein the at least one first physiological parameter comprises K , and wherein the personalized-target average glucose (GT) equals $AT/(K(1-AT))$ where AT is a target HbA1c level.

21. The system of claim 16 further comprising:

a display, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further: display the glucose level target.

22. The system of claim 21, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further:

receive a plurality of second glucose levels in the bodily fluid over a second time period after the first time period from the analyte sensor; and display an alarm when a glucose level from the plurality of second glucose levels is outside the glucose level target.

23. The system of claim 16, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further:

determine an error associated with the at least one first physiological

parameter; and

output a request for at least one new glucose level and/or at least one new HbA1c level when the error is at or greater than about 7%.

24. The system of claim 16, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further:

determine a metabolic age based on k_{age} and/or K .

25. The system of claim 16, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further:

receive a plurality of second glucose levels for a second time period after the first time period from the analyte sensor; and

determine a calculated glycated hemoglobin (cHbA1c) level based on (1) the k_{gi} , (2) the k_{age} , (3) the plurality of second glucose levels for the second time period, and (4) the first HbA1c level.

26. The system of claim 16, wherein the instructions which, when executed by the one or more processors, causes the one or more processors to further:

receive a second HbA1c level for an end of a second time period following the first time period;

determine at least one second physiological parameter corresponding to the at least one first physiological parameter; and

identify, based on a comparison of the at least one first physiological parameter and the at least one second physiological parameter, (1) a presence of an abnormal or diseased physiological condition and/or (2) an indicator of doping.

2019368318 27 Jan 2023

27. The system of claim 16, wherein the instructions, when executed, cause the one or more processors to:

 determine an insulin dosage based on the glucose level target; and
transmit the insulin dosage to an insulin pump system.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5A

5/14




FIG. 5B

6/14




FIG. 6

7/14




FIG. 7




FIG. 8

9/14




FIG. 9A




FIG. 9B




FIG. 9C

12/14




FIG. 10




FIG. 11




FIG. 12